Aalborg Universitet



Nationwide germline whole genome sequencing of 198 consecutive pediatric cancer patients reveals a high frequency of cancer prone syndromes

Byrjalsen, Anna; Hansen, Thomas V.O.; Stoltze, Ulrik K.; Mehrjouy, Mana M.; Barnkob, Nanna Moeller; Hjalgrim, Lisa L.; Mathiasen, René; Lautrup, Charlotte K.; Gregersen, Pernille A.; Hasle, Henrik; Wehner, Peder S.; Tuckuviene, Ruta; Sackett, Peter Wad; Laspiur, Adrian O.; Rossing, Maria; Marvig, Rasmus L.; Tommerup, Niels; Olsen, Tina Elisabeth; Scheie, David: Gupta, Ramneek: Gerdes, Anne Marie: Schmiegelow, Kield: Wadt, Karin Published in: **PLOS** Genetics

DOI (link to publication from Publisher): 10.1371/JOURNAL.PGEN.1009231

Creative Commons License CC BY 4.0

Publication date: 2020

Document Version Publisher's PDF, also known as Version of record

Link to publication from Aalborg University

Citation for published version (APA):

Byrjalsen, A., Hansen, T. V. O., Stoltze, U. K., Mehrjouy, M. M., Barnkob, N. M., Hjalgrim, L. L., Mathiasen, R., Lautrup, C. K., Gregersen, P. A., Hasle, H., Wehner, P. S., Tuckuviene, R., Sackett, P. W., Laspiur, A. O., Rossing, M., Marvig, R. L., Tommerup, N., Olsen, T. E., Scheie, D., ... Wadt, K. (2020). Nationwide germline whole genome sequencing of 198 consecutive pediatric cancer patients reveals a high frequency of cancer prone syndromes. PLOS Genetics, 16(12), Article e1009231. https://doi.org/10.1371/JOURNAL.PGEN.1009231

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain You may freely distribute the URL identifying the publication in the public portal -



Citation: Byrjalsen A, Hansen TVO, Stoltze UK, Mehrjouy MM, Barnkob NM, Hjalgrim LL, et al. (2020) Nationwide germline whole genome sequencing of 198 consecutive pediatric cancer patients reveals a high incidence of cancer prone syndromes. PLoS Genet 16(12): e1009231. https:// doi.org/10.1371/journal.pgen.1009231

Editor: Charis Eng, Cleveland Clinic Genomic Medicine Institute, UNITED STATES

Received: August 24, 2020

Accepted: October 28, 2020

Published: December 17, 2020

Peer Review History: PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: https://doi.org/10.1371/journal.pgen.1009231

Copyright: © 2020 Byrjalsen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the manuscript and its <u>Supporting</u> Information files.

RESEARCH ARTICLE

Nationwide germline whole genome sequencing of 198 consecutive pediatric cancer patients reveals a high incidence of cancer prone syndromes

Anna Byrjalsen ^{1,2}, Thomas V. O. Hansen^{1,2}, Ulrik K. Stoltze ¹, Mana M. Mehrjouy ^{1,2}, Nanna Moeller Barnkob ³, Lisa L. Hjalgrim ², René Mathiasen², Charlotte K. Lautrup⁴, Pernille A. Gregersen ⁵, Henrik Hasle ⁶, Peder S. Wehner ⁷, Ruta Tuckuviene⁸, Peter Wad Sackett ³, Adrian O. Laspiur³, Maria Rossing ⁹, Rasmus L. Marvig ⁹, Niels Tommerup¹⁰, Tina Elisabeth Olsen ¹¹, David Scheie¹¹, Ramneek Gupta ³, Anne-Marie Gerdes^{1‡}, Kjeld Schmiegelow ^{2,12‡}, Karin Wadt ^{1‡}*

Department of Clinical Genetics, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark,
 Department of Paediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet,
 Copenhagen, Denmark, 3 Department of Health Technology, Technical University of Denmark,
 Copenhagen, Denmark, 4 Department of Clinical Genetics, Aalborg University Hospital, Aalborg, Denmark,
 Department of Clinical Genetics, Aarhus University Hospital, Aarhus, Denmark, 6 Department of
 Paediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark, 7 Department of
 Paediatric Hematology and Oncology, H. C. Andersen Children's Hospital, Odense University Hospital,
 Odense, Denmark, 8 Department of Paediatrics and Adolescent Medicine, Aalborg University Hospital,
 Adalborg, Denmark, 9 Center for Genomic Medicine, Copenhagen University Hospital Rigshospitalet,
 Copenhagen, Denmark, 10 Department of Pathology, Copenhagen University Hospital Rigshospitalet,
 Copenhagen, Denmark, 12 Institute of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark

‡ These authors are share senior authors on this work. * karin.wadt@regionh.dk

Abstract

PURPOSE: Historically, cancer predisposition syndromes (CPSs) were rarely established for children with cancer. This nationwide, population-based study investigated how frequently children with cancer had or were likely to have a CPS. METHODS: Children (0–17 years) in Denmark with newly diagnosed cancer were invited to participate in whole-genome sequencing of germline DNA. Suspicion of CPS was assessed according to Jongmans'/ McGill Interactive Pediatric OncoGenetic Guidelines (MIPOGG) criteria and familial cancer diagnoses were verified using population-based registries. RESULTS: 198 of 235 (84.3%) eligible patients participated, of whom 94/198 (47.5%) carried pathogenic variants (PVs) in a CPS gene or had clinical features indicating CPS. Twenty-nine of 198 (14.6%) patients harbored a CPS, of whom 21/198 (10.6%) harbored a childhood-onset and 9/198 (4.5%) an adult-onset CPS. In addition, 23/198 (11.6%) patients carried a PV associated with biallelic CPS. Seven of the 54 (12.9%) patients carried two or more variants in different CPS genes. Seventy of 198 (35.4%) patients fulfilled the Jongmans' and/or MIPOGG criteria indicating an underlying CPS, including two of the 9 (22.2%) patients with an adult-onset CPS versus 18 of the 21 (85.7%) patients with a childhood-onset CPS (p = 0.0022), eight of the

Funding: This study was financially supported by the Danish Childhood Cancer Foundation (KS, https://boernecancerfonden.dk/), Rigshospitalet (AB, KW, https://www.rigshospitalet.dk/), The Danish Cancer Society (KS), the Foundation for Health Research of the Capital Region of Denmark (AMG, https://www.regionh.dk/til-fagfolk/ Forskning-og-innovation/finansiering-og-fonde/s% C3%B8g-regionale-midler/Sider/Region-Hovedstadens-forskningsmidler.aspx), The European Union's Interregional Öresund-Kattegat-Skagerrak grant (KS, https://interreg-oks.eu/), Aase and Ejnar Danielsen's Foundation (AMG, https:// danielsensfond.dk/), and Engineer Otto Christensen's Foundation (AB, no URL), the Danish National Research Foundation (RLM, https://dg.dk/ , grant number 126). No funding sources played a role in study design, data collection, analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

additional 23 (34.8%) patients with a heterozygous PV associated with biallelic CPS, and 42 patients without PVs. Children with a central nervous system (CNS) tumor had family members with CNS tumors more frequently than patients with other cancers (11/44, p = 0.04), but 42 of 44 (95.5%) cases did not have a PV in a CPS gene. CONCLUSION: These results demonstrate the value of systematically screening pediatric cancer patients for CPSs and indicate that a higher proportion of childhood cancers may be linked to predisposing germ-line variants than previously supposed.

Author summary

Traditionally pediatric cancer have been thought to be–mostly–caused by pure bad luck. In recent years, however, this notion has been challenged by novel findings as both maternal environmental exposure and genetic causes have been proven to increase the risk of certain pediatric cancers. With this study we have investigated a national cohort of pediatric cancer patients in Denmark. We have mapped family pedigree, made physical examination of the patients, and sequenced their genome, to get a 360-degree understanding of these patients. This revealed that a tenth of all patients carried a genetic variant causative of their cancer development. In addition, almost half of all patients were suspected of carrying a causative genetic variant based on tools that evaluate type of cancer, physical characteristics and family history. It also showed that tools to predict which patients carried a genetic variant did not identify all patients who in fact carried a genetic variant. Overall, roughly half of all patients were suspected of carrying an underlying genetic cause of their cancer, and a tenth had a verified underlying genetic variant predisposing to cancer pediatric cancer. This could suggest that the amount of pediatric cancer cases attributed to genetic factors may be even higher.

Introduction

In Europe, 15,000 children (1 in 300) are diagnosed with cancer each year.[1] Cancer can be attributed to genetic predisposition, exposure to carcinogens, and/or random mutations during cell division. Children are exposed to fewer carcinogens than adults.[2,3] Therefore, genetic predisposition and randomly acquired mutations are the major causes of most childhood cancers.

Cancer predisposition syndromes (CPSs) were previously considered rare among pediatric cancer patients, but increasing use of whole-exome sequencing (WES) and whole-genome sequencing (WGS) have identified up to 10% CPS among children, including several cases of CPS for adult-onset cancers not previously associated with childhood CPS. However, most studies investigated selected or single institution cohorts and included patients with specific diagnoses that were frequently associated with CPS.[4–6] Although some studies have included a broader range of pediatric cancer patients, [7–11] there have currently been no nationwide population-based studies. Moreover, most studies have focused on single nucleotide variants (SNVs) and few have included the effects of copy number variants (CNVs).[12]

Many clinical criteria have been developed to identify patients with CPS,[13–18] but these have not been validated in a national cohort.

Here we present the genetic SNV and CNV findings from the first 198 consecutive pediatric cancer patients included in the Danish, prospective, nationwide study Sequencing Tumor And Germline DNA—Implications for National Guidelines (STAGING).

Methods

Ethics statement

Ethical approval was obtained through the regional scientific ethical committee (the Ethical Scientific Committees for the Capital Region, H-15016782) and the Danish Data Protection Agency (RH-2016-219, I-Suite no: 04804). All parents/guardians and patients 15 years or older gave formal written consent to participation in this study.

Inclusion criteria and national setup

CPSs were defined as likely pathogenic or pathogenic variants (PVs) in a gene, predisposing the carrier to childhood- or adult-onset cancer. Between 1 July and 31 December 2016 we included 25 patients in the STAGING pilot study at Rigshospitalet (Copenhagen University Hospital, Denmark). On 1 January 2017, the study was expanded to all four pediatric oncology departments in Denmark. All patients were enrolled before June 2018.

Patients were eligible for inclusion if aged 0–17 years at diagnosis of a primary cancer including benign brain tumors, Langerhans cell histiocytosis (LCH), or myelodysplastic syndrome and parents spoke and read Danish.

Families were provided with written and oral information about the study by a research nurse or oncologist. A PhD student from STAGING (AB) or clinical geneticist provided genetic counselling to families interested in participating. Counselling sessions included pedigree construction (three generations), recording the child's clinical phenotypic features according to McGill Interactive Pediatric OncoGenetic Guidelines (MIPOGG)[18] and Jongmans' criteria[13] (Table 1), and explaining the potential consequences of genetic findings. These consequences included secondary findings, variants of unknown significance (VUS), implications of pathogenic findings associated with CPSs, and subsequent preventive and surveillance measures. Families choosing to enroll in the study were informed that PVs in 'actionable' genes listed by the American College of Medical Genetics and Genomics (ACMG)[19] would be disclosed to them. Families could select information regarding:

1: PVs in ACMG 'actionable' genes.

2: "1" and PVs in 314 known and putative cancer genes. Heterozygous variants in genes with solely recessive inheritance patterns were reported only if further familial genetic testing was warranted, in accordance with clinical guidelines.

3: In addition to "1" and "2", PVs in genes unrelated to CPSs (<u>Table 2</u>). Variants were only reported if clinical consequences were anticipated. Findings in these genes are not presented here.

Pedigrees covering 1st-3rd-generation family members were constructed for all patients. 1stdegree family members were parents and siblings, 2nd-degree family members were uncles/ aunts and grandparents, and 3rd-degree family members were cousins, grandparents' siblings and great-grandparents. Cancer diagnoses were verified using unique civil registration numbers, which link family members to medical records, including pathological descriptions of cancer, in the Danish Pathology Data Bank. Living family members gave consent, whereas medical records of deceased family members could be retrieved without consent.

DNA sampling and sequencing

Genomic DNA was isolated from peripheral blood samples. For patients with hematologic malignancies, blood samples were drawn after remission, otherwise skin biopsies were obtained. Parental blood samples were collected to establish whether variants were paternally or maternally derived or occurred *de novo*.

Table 1. Tools to identify patients at risk of a cancer predisposition syndrome. Excerpt from the updated Jong
mans' criteria[13] and McGill Interactive Pediatric OncoGenetic Guidelines (MIPOGG)[17].

JONGMANS' CRITERIA					
Criteria 1: Family history (3 generations)	Cancer history in the family: - 2 or more malignancies in family members <18 years of age - Any 1 st -degree relative with cancer <45 years of age - 2 or more 1 st - or 2 nd -degree relatives in same parental lineage with cancer <45 years of age Parents are consanguineous				
Criteria 2: Neoplasm indicating underlying CPS	E.g., Hypodiploid ALL, botryoid rhabdomyosarcoma of the urogenital tract, gastrointestinal stromal tumors, retinoblastoma, schwannoma, subependymal giant cell astrocytoma				
Criteria 3: Tumor analysis suggesting germline predisposition	E.g., Microsatellite instability in constitutional mismatch repair deficiency, loss of heterozygosity, other mutational signatures				
Criteria 4: Patient with 2 or more malignancies	Secondary, bilateral, multifocal, or metachronous cancers				
Criteria 5: Congenital or other phenotypic anomalies	Congenital anomalies (oral clefting, skeletal anomalies, facial dysmorphism) Developmental delay Growth anomalies Skin aberrations (café-au-lait spots, hypopigmentation, sun sensitivity) Immune deficiency				
Criteria 6: Excessive toxicity related to cancer treatment	This criterion is not well defined and, based on an individual assessment by the pediatric oncologist/researcher, we have chosen not to include this criterion in this paper				
	MIPOGG CRITERIA				
	Universal criteria				
Anamnestic criteria	 >1 primary tumor Bilateral/multifocal primary tumors Dysmorphic features/congenital abnormalities that the clinician deems to be related to cancer predisposition 				
Family anamnestic criteria	 Known cancer predisposition syndrome in the family Close relative* with cancer <18 years OR a parent/sibling/half-sibling with cancer at <50 years Close relative* with the same cancer type or same organ affected by cancer at any age Close relative* with multiple primary tumors 				
	Tumors for direct referral				
Tumors of the central nervous system and ocular tumors	Atypical teratoid rhabdoid tumor, choroid plexus carcinoma, dysplastic cerebellar gangliocytoma, endolymphatic sac tumor, hemangioblastoma, optic pathway glioma, pineoblastoma, pituitary adenoma, retinoblastoma, subependymal giant cell astrocytoma, vestibular schwannoma				
Renal and neuroblastic tumors	Cystic nephroma, renal angiomyolipoma, renal cell carcinoma, renal rhabdoid tumor				
Bone and soft-tissue tumors	Desmoid tumor, extrarenal rhabdoid tumor, Gardner fibroma, malignant periphery nerve sheath tumor, nasal chondromesenchymal hamartoma				
Other tumors	Adrenocortical carcinoma, cardiac rhabdomyoma, colorectal carcinoma, gastrointestinal stromal tumor, hepatoblastoma, medullary thyroid cancer, ovarian Sertoli–Leydig cell tumor, parathyroid tumor, pheochromocytoma, paraganglioma, pleuropulmonary blastoma, trichilemmoma, small cell carcinoma of the ovary of hypercalcemic type, carcinoma of the breast, lung, cervix, uterus, or bladder				

https://doi.org/10.1371/journal.pgen.1009231.t001

WGS was performed by the Norwegian Sequencing Center (Oslo, Norway) for the pilot study and by the Beijing Genomics Institute (Hong Kong, China) for the national study using the HiSeqX platform (Illumina, San Diego, CA, USA) with paired-end sequencing of

Level 1	Information regarding pathogenic or likely pathogenic variants in genes identified by the American College of Medical Genetics[19]. These genes are 'actionable' i.e., there are potential preventive, treatment, or surveillance modalities available. Half of these genes are related to CPS (primary findings); the others are related to cardiac disease, metabolic disorders, or familial hypercholesterolemia (secondary findings).
Level 2	In addition to the genes listed at level 1, information regarding pathogenic or likely pathogenic variants in other known or putative CPS genes (from the list of 314 CPS genes found in S 1A Data). These were considered primary findings. However, if there was no known correlation between the clinical phenotype and the gene in question, the variant was considered a secondary finding.
Level 3	In addition to the genes listed at levels 1 and 2, families would also receive information regarding pathogenic or likely pathogenic variants in other genes not related to CPS (not presented in this paper). These were considered secondary findings.

Table 2. Families could choose to receive one of the following levels of feedback from germline WGS of the affected child.

https://doi.org/10.1371/journal.pgen.1009231.t002

150-bp reads and 30× average coverage. Reads were mapped to the hg19 reference genome sequence (GRCh37.p13; RefSeq assembly accession GCF_000001405.25) using BWA version 0.7.12,[20] and biobambam2 version 2.0.27[21] was used to sort and mark duplicate reads. Germline SNVs and indel variants were called with HaplotypeCaller using GATK version 3.8[22] or the DNAseq pipeline (Sentieon, San Jose, CA, USA). VarSeq software (version 2.2.0, Golden Helix, Bozeman, MT, USA) was used to annotate variants. Moreover, filtration was based on read depth \geq 8, genotype quality \geq 20, and variant allele frequency $(VAF) \ge 0.2$, and sequence ontology was used to exclude intronic and intergenic variants and variants located in the 3' and 5' untranslated region (UTR) prior to evaluation. Integrative Genomics Viewer (IGV, version 2.8.2, Boston, MA, USA) was used to visualize read alignments. Manta and CNVkit were applied for calling larger structural rearrangements. [23,24] All variants were reported according to HGVS nomenclature guidelines.[25] WGS data were filtered for PVs in the 59 ACMG 'actionable' genes and 314 cancer genes (S1 Data). The cancer gene panel was selected from Zhang *et al.*,[7] Rahman,[26] and novel genes recently linked to childhood or adult CPSs. All variants with a minor allele frequency of <1% in any large population (gnomAD) were tabulated. For CPS genes with higher variant frequencies in the general population (e.g., ATM, CHEK2), a separate filter was used. We did not apply a specific variant filter to identify mosaicism. Variants were assessed by a team of clinical geneticists and molecular biologists based on variant type (e.g., frameshift, nonsense, missense), computational predictions of effect on protein and RNA function (e.g., Combined Annotation Dependent Depletion [CADD], PHRED quality score, ADA splice prediction score), [27] and database searches for published literature on each variant. Moreover, we used Alamut Visual 2.10 to evaluate variants effect on splicing (https://www. interactive-biosoftware.com/alamut-visual/). The effects of variants were considered significant if the scores of at least three programs were reduced >10% or a strong cryptic acceptor or donor site was generated. Variants were classified as pathogenic (class 5), likely pathogenic (class 4), VUS (class 3), likely benign (class 2), and benign (class 1).[28] Class 4 and 5 variants were designated 'PVs'. Class 3 variants, especially those that potentially matched the child's diagnosis, were further investigated by segregation analysis and splice predictions, and tumor RNA sequencing was used to assess loss-of-heterozygosity (LOH) if tissue was available (Fig 1). In addition, we used the machine-learning tool ORVAL to predict whether combinations of genetic variants were likely to be pathogenic. [29] Variants were discussed at regular multidisciplinary meetings by pediatric oncologists, clinical geneticists, and bioinformaticians. PVs were verified by Sanger or next-generation sequencing before parents were informed.



Fig 1. Inclusion and sequencing strategy. Variants presented are in genes associated with CPS. All variants of unknown significance have a CADD-PHRED score >20 and an allele frequency <1%. ¹Patients whose parents were not able to give informed consent due to language barriers or social issues (mainly parental psychiatric/severe somatic disease).

https://doi.org/10.1371/journal.pgen.1009231.g001

Statistical analysis

Patient/parental characteristics were compared using Pearson chi-square test. Two-sided *P*-values below 0.05 were considered statistically significant. Statistical calculations were carried out using the R software version 3.6.0.

Results

Patient characteristics

Of 248 consecutive pediatric cancer patients that fulfilled the inclusion criteria, 198 families consented to participation (Fig 1, Table 3). The included patients did not differ significantly (p>0.05) from the 35 patients that declined to participate with regard to sex, age, or diagnoses. Of 198 families, 155/198 (78.3%) opted for feedback on all findings, 24/198 (12.1%) opted for feedback on PVs in 'actionable' genes and 314 cancer genes, and 19/198 (9.6%) opted for feedback on PVs in ACMG 'actionable' genes only. There were no significant differences (p>0.05) in parental age, educational level, or income among families opting for the three levels of feedback.

Patients with known and suspected CPSs

Overall, 94/198 (47.5%) patients carried a PV in a CPS gene or were suspected of having an underlying CPS based on Jongmans'/MIPOGG criteria or family cancer history (Fig 2).

Twenty-nine of 198 (14.6%) patients carried PVs in at least one CPS gene, including four patients with trisomy 21. Of these, 21/198 (10.6%) had PVs in genes predisposing toward childhood-onset CPS, including *CDC73*, *DDX41* (biallelic, putative childhood-onset cancer gene), *LTZR1*, *NF1*, *RB1*, *SDHC*, *SMARCA4*, *TP53*, and *TSC2*, uniparental disomy (UPD) of chromosome 11p (clinical analysis), and trisomy 21.[30]

In addition, 9/198 (4.5%) patients had PVs in genes predisposing toward adult-onset CPS, one of whom also carried a deletion in a childhood-onset CPS gene. Adult-onset CPS variants were identified in *APC*, *ATM*, *AXIN2*, *BARD1*, *BRCA2*, *CHEK2*, *MUTYH*, and *PALB2*, some conferred a high risk of cancer[31–33] whereas others conferred a moderate risk[34–38] (Table 4). The specific variants in *APC* and *ATM* are only associated with an adult-onset CPS, had the specific variants been associated with childhood-onset CPS, these genes would have been listed above.

These 29 patients had 31 PVs in total, including seven frameshift, five nonsense, eight missense, and three splice-site variants. Three variants were larger deletions of at least one exon, one patient had UPD 11p, and four patients had trisomy 21.

Some CPSs occurred in several patients (Table 4). Two patients had PVs in two CPS genes: a patient with LCH had PVs in *BRCA2* and *AXIN2*; a patient with a malignant peripheral nerve sheath tumor had PVs in *NF1* and *PALB2*. All CPS PVs were monoallelic, except for one patient with biallelic PVs in *DDX41*.[39]

Of the 21 childhood-associated CPSs 18 (85.7%) had previously established links between genotype (e.g., trisomy 21 and leukemia) and cancers (Table 4). This study identified a PV in eight of the 21 (38.1%) pediatric CPS patients, whereas 13/21 (61.9%) patients had a previously established genetic predisposition syndrome (e.g., NF1 or trisomy 21). Such a connection was established through clinical diagnosis and/or genetic testing. Among these 21 patients, only one had a family member diagnosed with cancer before 18 years of age (Table 5).

SexImage: sec: sec: sec: sec: sec: sec: sec: se		N (%)
Male121 (61.1%)Female77 (38.9%)Age at diagnosis77 (38.9%)0-5 years104 (52.5%)6-10 years41 (20.7%)11-15 years39 (19.7%)16-18 years14 (7.0%)Diagnosis14 (7.0%)Precursor B-ALL45Lymphoma22AML/CML/other myeloid leukemia17Precursor T-ALL45Langerhans call histicytosis6Myelodysplastic syndrome3Mixed lineage ALL2Tumors of the central nervous system44 (22.2%)Low-grade glioma, WHO grade 1-1117High-grade glioma, WHO grade 11-11V6Ependymoma2Schwannoma2Other10Solid tumors49 (25.0%)Wilms tumor8Nearcoma5Retinoblastoma5Retinoblastoma5Retinoblastoma12Lowing's sarcoma4Malant peripheral nerve sheath tumor12Level of feedback125 (78.2%)Limited feedback126 (12.1%)No feedback126 (12.1%)No feedback126 (12.1%)	Sex	
Female77 (38.9%)Age at diagnosis	Male	121 (61.1%)
Age at diagnosis0-5 years104 (52.5%)6-10 years41 (20.7%)11-15 years39 (19.7%)16-18 years14 (7.0%)Diagnosis1Hematologic cancer105 (53.0%)Precursor B-ALL45Lymphoma22AML/CML/other myeloid leukemia17Precursor T-ALL10Langerhans cell histiccytosis6Myelodysplastic syndrome3Miked lineage ALL2Tumors of the central nervous system44 (22.2%)Low-grade glioma, WHO grade 1-II17High-grade glioma, WHO grade 1-II17High-grade glioma, WHO grade 1-II2Other3Schwannoma2Schwannoma2Schwannoma2Schwannoma44 (25.0%)Wins tumor8Neuroblastoma5Setionalistoma5Setionalistoma5Setionalistoma5Weing's sarcoma4Maignant peripheral nerve sheath tumor11Other12Fuil fleedback125 (78.2%)Linniet feedback24 (12.1%)No feedback24 (12.1%)No feedback126 (0.6%)	Female	77 (38.9%)
0-5 years104 (52.5%)6-10 years41 (20.7%)11-15 years39 (19.7%)16-18 years39 (19.7%)16-18 years14 (7.0%)Diagnosis	Age at diagnosis	
6-10 years41 (20.7%)11-15 years39 (19.7%)16-18 years14 (7.0%)Diagnosis14 (7.0%)Diagnosis105 (53.0%)Precursor B-ALL45Lymphoma22AML/CML/other myeloid leukemia17Precursor T-ALL10Langerhans cell histiocytosis6Myelodysplastic syndrome3Mixed lineage ALL2Tumors of the central nervous system44 (22.2%)Low-grade glioma, WHO grade I-II17High grade glioma, WHO grade III-IV6Ependymona4AT/RT3Medulloblastoma2Schwannoma2Other10Solid tumors8Neuroblastoma6Other5Retinoblastoma5Ewing's sarcoma4Malignant peripheral nerve sheath tumor1Other12Luevel of feedback125 (78.2%)Limited feedback24 (12.1%)No feedback155 (78.2%)Limited feedback19 (9.6%)	0–5 years	104 (52.5%)
11-15 years39 (19.7%)16-18 years14 (7.0%)Diagnosis14 (7.0%)Hematologic cancer105 (53.0%)Precursor B-ALL45Lymphoma22AML/CML/other myeloid leukemia17Precursor T-ALL10Langerhans cell histiocytosis6Myelodysplastic syndrome3Mixed lineage ALL2Tumors of the central nervous system44 (22.2%)Low-grade glioma, WHO grade I-II17High-grade glioma, WHO grade I-II17High-grade glioma, WHO grade I-II6Ependymoma4AT/RT3Medulloblastoma2Schwannoma2Other10Solid tumors49 (25.0%)Wilm tumor8Neuroblastoma5Ewing's sarcoma4Athabdomyosarcoma4Other12Lurel of feedback155 (78.2%)Limit deedback24 (12.1%)No feedback19 (9.6%)	6–10 years	41 (20.7%)
16-18 years14 (7.0%)DiagnosisIHematologic cancer105 (53.0%)Precursor B-ALL45Lymphoma22AML/CML/other myeloid leukemia17Precursor T-ALL10Langerhans cell histiocytosis6Myelodysplastic syndrome3Mixed lineage ALL2Tumors of the central nervous system44 (22.2%)Low-grade glioma, WHO grade 1-II17High-grade glioma, WHO grade III-IV6Ependymoma4AT/RT3Medulloblastoma2Schwannoma2Other10Solid tumors49 (25.0%)Wilms tumor8Neuroblastoma5Ewing's sarcoma4Other1Other1Other1Other5Ewing's sarcoma4Atlant5Ewing's sarcoma4Malignant peripheral nerve sheath tumor1Other12Lurel of feedback155 (78.2%)Limited feedback24 (12.1%)No feedback24 (12.1%)	11-15 years	39 (19.7%)
DiagnosisIHematologic cancer105 (53.0%)Precursor B-ALL45Lymphoma22AML/CML/other myeloid leukemia17Precursor T-ALL10Langerhans cell histicytosis6Myelodysplastic syndrome3Mixed lineage ALL2Tumors of the central nervous system44 (22.2%)Low-grade glioma, WHO grade I-II17High-grade glioma, WHO grade II-IV6Ependymoma4AT/RT3Medulloblastoma2Schwannoma2Other10Solid tumors49 (25.0%)Wilms tumor8Neuroblastoma5Ewing's sarcoma4Malignant peripheral nerve sheath tumor1Other12Level of feedback24 (12.1%)No feedback24 (12.1%)No feedback19 (9.6%)	16–18 years	14 (7.0%)
Hematologic cancer105 (53.0%)Precursor B-ALL45Lymphoma22AML/CML/other myeloid leukemia17Precursor T-ALL10Langerhans cell histiocytosis6Myelodysplastic syndrome3Mixed lineage ALL2Tumors of the central nervous system44 (22.2%)Low-grade glioma, WHO grade II-II17High-grade glioma, WHO grade II-II17High-grade glioma, WHO grade III-IV6Ependymoma4AT/RT3Medulloblastoma2Schwannoma2Other10Solid tumors8Neuroblastoma5Retinoblastoma5Sexarcoma4Malignant peripheral nerve sheath tumor1Other12Level of feedback155 (78.2%)Limit deedback19 (9.6%)Full fineet of longmans' criteria19 (9.6%)	Diagnosis	
Precursor B-ALL45Lymphoma22AML/CML/other myeloid leukemia17Precursor T-ALL10Langerhans cell histiocytosis6Myelodysplastic syndrome3Mixed lineage ALL2Tumors of the central nervous system44 (22.2%)Low-grade glioma, WHO grade I-II17High-grade glioma, WHO grade III-IV6Ependymoma4AT/RT3Medulloblastoma2Schwannoma2Other10Solid tumors49 (25.0%)Wilms tumor8Rhabdomyosarcoma5Ewing's sarcoma4Malignant peripheral nerve sheath tumor1Other12Level of feedback155 (78.2%)Limited feedback19 (9.6%)Fulfilment of longmans' criteria14	Hematologic cancer	105 (53.0%)
Lymphoma22AML/CML/other myeloid leukemia17Precursor T-ALL10Langerhans cell histiocytosis6Myelodysplastic syndrome3Mixed lineage ALL2Tumors of the central nervous system44 (22.2%)Low-grade glioma, WHO grade 1-II17High-grade glioma, WHO grade III-IV6Ependymoma4AT/RT3Medulloblastoma2Schwannoma2Other10Solid tumors49 (25.0%)Wilms tumor8Neuroblastoma5Retinoblastoma5Schwanna5Rubdomyosarcoma5Retinoblastoma5Ewing's sarcoma4Malignant peripheral nerve sheath tumor1Other12Level of feedback155 (78.2%)Limited feedback19 (9.6%)Fulfilment of longmans' criteria19	Precursor B-ALL	45
AML/CML/other myeloid leukemia17Precursor T-ALL10Langerhans cell histiocytosis6Myelodysplastic syndrome3Mixed lineage ALL2Tumors of the central nervous system44 (22.2%)Low-grade glioma, WHO grade 1–II17High-grade glioma, WHO grade III–IV6Ependymoma4AT/RT3Medulloblastoma2Schwannoma2Other10Solid tumors49 (25.0%)Wilms tumor8Neuroblastoma5Retinoblastoma5Exing's sarcoma4Malignant peripheral nerve sheath tumor1Other12Level of feedback155 (78.2%)Limited feedback24 (12.1%)No feedback159 (9.6%)Fulfillment of longmans' criteria9	Lymphoma	22
Precursor T-ALL10Langerhans cell histicytosis6Myelodysplastic syndrome3Mixed lineage ALL2Tumors of the central nervous system44 (22.2%)Low-grade glioma, WHO grade I-II17High-grade glioma, WHO grade III-IV6Ependymoma4AT/RT3Medulloblastoma2Schwannoma2Other10Solid tumors49 (25.0%)Wilms tumor8Neuroblastoma5Retinoblastoma5Retinoblastoma5Retinoblastoma1Other10Solid stoma8Neuroblastoma4Athabdomyosarcoma6Osteosarcoma5Ewing's sarcoma4Malignant peripheral nerve sheath tumor1Other12Level of feedback155 (78.2%)Limited feedback159 (9.6%)Fulfilment of longmans' criteria19 (9.6%)	AML/CML/other myeloid leukemia	17
Langerhans cell histiccytosis6Myelodysplastic syndrome3Mixed lineage ALL2Tumors of the central nervous system44 (22.2%)Low-grade glioma, WHO grade I-II17High-grade glioma, WHO grade III-IV6Ependymoma4AT/RT3Medulloblastoma2Schwannoma2Other10Solid tumors8Neuroblastoma5Retinoblastoma5Retinoblastoma5Retinoblastoma5Ewing's sarcoma4Malignant peripheral nerve sheath tumor1Other12Level of feedback155 (78.2%)Limited feedback19 (9.6%)Fulfillement of Jongmans' criteria19 (9.6%)	Precursor T-ALL	10
Myelodysplastic syndrome3Mixed lineage ALL2Tumors of the central nervous system44 (22.2%)Low-grade glioma, WHO grade I-II17High-grade glioma, WHO grade III-IV6Ependymoma4AT/RT3Medulloblastoma2Schwannoma2Other10Solid tumors49 (25.0%)Wilms tumor8Neuroblastoma5Retinoblastoma5Schwannoma5Other10Solid tumors4Malgnant peripheral nerve sheath tumor1Other12Level of feedback155 (78.2%)Limited feedback24 (12.1%)No feedback19 (9.6%)Fulfillment of Jongmans' criteria19 (9.6%)	Langerhans cell histiocytosis	6
Mixed lineage ALL2Tumors of the central nervous system44 (22.2%)Low-grade glioma, WHO grade I-II17High-grade glioma, WHO grade III-IV6Ependymoma4AT/RT3Medulloblastoma2Schwannoma2Other10Solid tumors49 (25.0%)Wilms tumor8Neuroblastoma5Retinoblastoma5Retinoblastoma5Eving's sarcoma4Malignant peripheral nerve sheath tumor1Other12Level of feedback155 (78.2%)Limited feedback24 (12.1%)No feedback19 (9.6%)Fulfillment of Jongmans' criteria1	Myelodysplastic syndrome	3
Tumors of the central nervous system44 (22.2%)Low-grade glioma, WHO grade I-II17High-grade glioma, WHO grade III-IV6Ependymoma4AT/RT3Medulloblastoma2Schwannoma2Other10Solid tumors49 (25.0%)Wilms tumor8Neuroblastoma5Retinoblastoma5Osteosarcoma5Retinoblastoma5Ewing's sarcoma4Malignant peripheral nerve sheath tumor1Other12Level of feedback155 (78.2%)Limited feedback19 (9.6%)Fulfillment of Jongmans' criteria5	Mixed lineage ALL	2
Low-grade glioma, WHO grade II-II17High-grade glioma, WHO grade III-IV6Ependymoma4AT/RT3Medulloblastoma2Schwannoma2Other10Solid tumors49 (25.0%)Wilms tumor8Neuroblastoma5Retinoblastoma5Retinoblastoma5Ewing's sarcoma4Malignant peripheral nerve sheath tumor1Other12Level of feedback155 (78.2%)Limited feedback19 (9.6%)Fulfillment of Jongmans' criteria5	Tumors of the central nervous system	44 (22.2%)
High-grade glioma, WHO grade III-IV6Ependymoma4AT/RT3Medulloblastoma2Schwannoma2Other10Solid tumors49 (25.0%)Wilms tumor8Neuroblastoma8Rhabdomyosarcoma6Osteosarcoma5Retinoblastoma5Ewing's sarcoma4Malignant peripheral nerve sheath tumor1Other12Level of feedback155 (78.2%)Limited feedback19 (9.6%)Fulfillment of Jongmans' criteria19 (9.6%)	Low-grade glioma, WHO grade I–II	17
Ependymoma4AT/RT3Medulloblastoma2Schwannoma2Other10Solid tumors49 (25.0%)Wilms tumor8Neuroblastoma8Rhabdomyosarcoma6Osteosarcoma5Retinoblastoma5Ewing's sarcoma4Malignant peripheral nerve sheath tumor1Other12Level of feedback155 (78.2%)Limited feedback19 (9.6%)Fullflement of Jongmans' criteria19 (9.6%)	High-grade glioma, WHO grade III–IV	6
AT/RT3Medulloblastoma2Schwannoma2Other10Solid tumors49 (25.0%)Wilms tumor8Neuroblastoma8Rhabdomyosarcoma6Osteosarcoma5Retinoblastoma5Ewing's sarcoma4Malignant peripheral nerve sheath tumor1Other12Level of feedback155 (78.2%)Limited feedback19 (9.6%)Fulfillment of Jongmans' criteria5	Ependymoma	4
Medulloblastoma2Schwannoma2Other10Solid tumors49 (25.0%)Wilms tumor8Neuroblastoma8Rhabdomyosarcoma6Osteosarcoma5Retinoblastoma5Ewing's sarcoma4Malignant peripheral nerve sheath tumor1Other12Level of feedback155 (78.2%)Full feedback155 (78.2%)Limited feedback19 (9.6%)Fulfillment of Jongmans' criteria1	AT/RT	3
Schwannoma2Other10Solid tumors49 (25.0%)Wilms tumor8Neuroblastoma8Rhabdomyosarcoma6Osteosarcoma5Retinoblastoma5Ewing's sarcoma4Malignant peripheral nerve sheath tumor1Other12Level of feedback155 (78.2%)Full feedback155 (78.2%)Limited feedback19 (9.6%)Fulfillment of Jongmans' criteria1	Medulloblastoma	2
Other10Solid tumors49 (25.0%)Wilms tumor8Neuroblastoma8Rhabdomyosarcoma6Osteosarcoma5Retinoblastoma5Ewing's sarcoma4Malignant peripheral nerve sheath tumor1Other12Level of feedback155 (78.2%)Full feedback155 (78.2%)Limited feedback19 (9.6%)Fulfillment of Jongmans' criteria1	Schwannoma	2
Solid tumors49 (25.0%)Wilms tumor8Neuroblastoma8Rhabdomyosarcoma6Osteosarcoma5Retinoblastoma5Ewing's sarcoma4Malignant peripheral nerve sheath tumor1Other12Level of feedback155 (78.2%)Full feedback155 (78.2%)Limited feedback19 (9.6%)Fulfillment of Jongmans' criteria1	Other	10
Wilms tumor8Neuroblastoma8Rhabdomyosarcoma6Osteosarcoma5Retinoblastoma5Ewing's sarcoma4Malignant peripheral nerve sheath tumor1Other12Level of feedback12Full feedback155 (78.2%)Limited feedback24 (12.1%)No feedback19 (9.6%)Fulfillment of Jongmans' criteria1	Solid tumors	49 (25.0%)
Neuroblastoma8Rhabdomyosarcoma6Osteosarcoma5Retinoblastoma5Ewing's sarcoma4Malignant peripheral nerve sheath tumor1Other12Level of feedback12Full feedback155 (78.2%)Limited feedback24 (12.1%)No feedback19 (9.6%)Fulfillment of Jongmans' criteria1	Wilms tumor	8
Rhabdomyosarcoma6Osteosarcoma5Retinoblastoma5Ewing's sarcoma4Malignant peripheral nerve sheath tumor1Other12Level of feedback1Full feedback155 (78.2%)Limited feedback24 (12.1%)No feedback19 (9.6%)Fulfillment of Jongmans' criteria1	Neuroblastoma	8
Osteosarcoma5Retinoblastoma5Ewing's sarcoma4Malignant peripheral nerve sheath tumor1Other12Level of feedback155 (78.2%)Full feedback155 (78.2%)Limited feedback24 (12.1%)No feedback19 (9.6%)Fulfillment of Jongmans' criteria1	Rhabdomyosarcoma	6
Retinoblastoma5Ewing's sarcoma4Malignant peripheral nerve sheath tumor1Other12Level of feedback12Full feedback155 (78.2%)Limited feedback24 (12.1%)No feedback19 (9.6%)Fulfillment of Jongmans' criteria1	Osteosarcoma	5
Ewing's sarcoma4Malignant peripheral nerve sheath tumor1Other12Level of feedback12Full feedback155 (78.2%)Limited feedback24 (12.1%)No feedback19 (9.6%)Fulfillment of Jongmans' criteria1	Retinoblastoma	5
Malignant peripheral nerve sheath tumor1Other12Level of feedback15Full feedback155 (78.2%)Limited feedback24 (12.1%)No feedback19 (9.6%)Fulfillment of Jongmans' criteria19 (9.6%)	Ewing's sarcoma	4
Other12Level of feedback155 (78.2%)Full feedback155 (78.2%)Limited feedback24 (12.1%)No feedback19 (9.6%)Fulfillment of Jongmans' criteria19 (9.6%)	Malignant peripheral nerve sheath tumor	1
Level of feedbackImage: Image: Im	Other	12
Full feedback155 (78.2%)Limited feedback24 (12.1%)No feedback19 (9.6%)Fulfillment of Jongmans' criteria19 (9.6%)	Level of feedback	
Limited feedback 24 (12.1%) No feedback 19 (9.6%) Fulfillment of Jongmans' criteria 19 (9.6%)	Full feedback	155 (78.2%)
No feedback 19 (9.6%) Fulfillment of Jongmans' criteria 19	Limited feedback	24 (12.1%)
Fulfillment of Jongmans' criteria	No feedback	19 (9.6%)
· • • • • • • • • • • • • • • • • • • •	Fulfillment of Jongmans' criteria	
Fulfilled one or more criteria 56 (28.3%)	Fulfilled one or more criteria	56 (28.3%)
Did not fulfill any criteria 142 (71.7%)	Did not fulfill any criteria	142 (71.7%)
Referral for genetic evaluation recommended by MIPOGG	Referral for genetic evaluation recommended by MIPOGG	
Referral recommended 64 (32.3%)	Referral recommended	64 (32.3%)
Referral not recommended 134 (67.7%)	Referral not recommended	134 (67.7%)

Table 3. Patients distributed according to sex, age at diagnosis, diagnosis, level of feedback and fulfillment of the Jongmans' and MIPOGGs criteria.

https://doi.org/10.1371/journal.pgen.1009231.t003



Fig 2. Triangle of patients with confirmed or suspected underlying cancer predisposition syndrome. Patients fulfilling criteria for more than one level of the triangle were only counted once, closest to the top of the triangle. The column on the left shows the number of pathogenic variants on each level. The column on the right shows the number of patients on each level.

https://doi.org/10.1371/journal.pgen.1009231.g002

PVs in biallelic CPS

Twenty-seven of 198 (13.6%) patients carried one (n = 22) or two (n = 1, *FANCM* and *ADA*) PVs predisposing toward CPS through biallelic inheritance, of whom four also had a PV in a monoallelic CPS gene (Table 6). Variants were found in *ADA*, *ATR*, *EFL1*, *ERCC3*, *FANCA/C/ E/I/L/M*, *NBN*, *POLH*, *RECQL*, *RECQL4*, *RINT1*, *WRAP53*, and *XPC* (Fig 2).

Seven of the 198 (3.5%) patients carried two or more PVs/trisomy 21 (Table 7). Of these seven patients, one carried variants bioinformatically predicted to be oligogenically pathogenic. This patient carried biallelic variants in *DDX41* and a monoallelic variant in *NBN*. The digenic combination of a single *DDX41* variant and the *NBN* variant were also predicted to be pathogenic. No variant combinations in the six remaining patients were predicted to be oligogenically pathogenic.

Variants of unknown significance

All 198 patients carried VUS in one or more CPS genes. VUS with a frequency <1% and a CADD/PHRED score >20 are listed in <u>S1 Data</u>. Thirty-nine of 198 (19.7%) patients had a

Diagnosis	Gene	Gene Variant P		Corresponding to phenotype of the patient	Inherited (M/ P) ¹ / <i>de novo</i>	CADD-PHRED ² score	
Pathogenic/likely pathogenic	variants (chi	ldhood onset)		•			
Acute myeloid leukemia	CDC73	c.358C>T	p.(Arg120*)	-	-	37.0	
Plasmacytoid dendritic cell leukemia	DDX41 ³ DDX41	c.962C>T c.937G>C	p.(Pro321Leu) p.(Gly313Arg)	++	M P	31.0 32.0	
Osteosarcoma	LZTR1	c.955C>T	p.(Gln319*)	-	-	38.0	
Optic nerve glioma	NF1	c.5242C>T	p.(Arg1748*)	+	М	38.0	
Acute myeloid leukemia	NF1	c.288+1delG	p.(?)	+	-	34.0	
Malignant peripheral nerve sheath tumor ⁴	NF1	c.61-22171_4110+2458del (deletion of exon 2–30)	p. (Leu21_Gln1370del)	+	М	-	
Pilocytic astrocytoma	NF1	c.2033dupC	p.(Ile679Aspfs*21)	+	-	34.0	
Retinoblastoma	RB1	c.1735C>T	p.(Arg579*)	+	-	36.0	
Retinoblastoma	RB1	c.409_412delGAAA	p.(Glu137Leufs*15)	+	Р	36.0	
Retinoblastoma	RB1	c.219_220delAG	p.(Arg73Serfs*36)	+	De novo	31.0	
Retinoblastoma	RB1	c.2663+2T>C	p.(?)	+	-	25.2	
Acute promyelocytic leukemia	SDHC	c.148C>T	p.(Arg50Cys)	-	-	34.0	
Small cell carcinoma ⁵	SMARCA4 ⁶	c.2002-625_2124-1045del (deletion of exon 14)	p.(Glu669Cysfs*7)	+	-		
Precursor B-cell acute lymphoblastic leukemia	TP53	c.637C>G	p.(Arg213Gly)	+	Р	28.4	
Osteosarcoma	TP53	c.818G>A	p.(Arg273His)	+	De novo	27.3	
Subependymal giant cell astrocytoma	TSC2	c.4141dupC	p.(Leu1382Profs*32)	+	De novo	23.5	
Wilms tumor ⁷	Paternal uni Beckwith–W	parental disomy of chromosome iedemann syndrome	11, corresponding to	+	Р	-	
Acute megakaryoblastic leukemia ⁸	47,XY,+21			+	-	-	
Acute megakaryoblastic leukemia ⁸	47,XY,+21			+	-	-	
Hodgkins lymphoma	47,XX,+21			+	-	-	
Acute lymphoblastic leukemia	47,XX,+21			+	-	-	
		Pathogenic/likely	pathogenic variants (adu	ılt onset)			
Wilms tumor	APC ^{9, 10}	c.3920T>A	p.(Ile1307Lys)	-	-	5.3	
Neuroblastoma	APC ^{9, 10}	c.3920T>A	p.(Ile1307Lys)	-	-	5.3	
Rhabdomyosarcoma	ATM ^{9, 10}	c.9023G>C	p.(Arg3008Pro)	-	-	32.0	
Wilms tumor	BARD1 ¹⁰	g.215591264-215774591 (Deletion of exon 1–11)	p.(?)	-	-	-	
Langerhans cell histiocytosis	BRCA2 AXIN2	c.5722_5723delCT c.815+1G>A	p.(Leu1908Argfs*2) p.(?)	-	M M	21.2 24.5	
T-cell acute lymphoblastic leukemia	BRCA2	c.6486_6489delACAA	p.(Lys2162Asnfs*5)	-	-	29.1	
T-cell acute lymphoblastic leukemia	CHEK2 ¹⁰	c.1100del	p.(Thr367Metfs*15)	-	-	35.0	
Precursor B-cell acute	MUTYH ¹⁰	c.536A>G	p.(Tyr179Cys)	-	-	24.7	

Table 4. Pathogenic and likely pathogenic variants in cancer predisposition genes.

(Continued)

Table 4. (Continued)

Diagnosis	Gene	Variant	Protein	Corresponding to phenotype of the patient	Inherited (M/ P) ¹ / <i>de novo</i>	CADD-PHRED ² score			
Pathogenic/likely pathogenic	Pathogenic/likely pathogenic variants (childhood onset)								
Malignant peripheral nerve sheath tumor ⁴	PALB2	c.2736G>A	p.(Trp912*)	-	Р	41.0			

- Value not known/applicable (e.g., parents not tested)

¹M: maternally inherited, P: paternally inherited

²CADD: combined annotation dependent depletion, PHRED: quality score

³Putative childhood CPS gene

⁴Same patient carrying the NF1 deletion and PALB2 mutation

⁵The initial diagnosis (synovial sarcoma) was revised later revised

⁶Validation in process

⁷Detected by clinical analysis

⁸These patients are twin brothers

⁹The specific variants in *APC* and *ATM* are only associated with an adult-onset cancer predisposition syndrome; had the variant been associated with childhood cancer predisposition syndrome, these genes would have been listed above.

¹⁰These variants confer a moderate risk of cancer in adulthood

https://doi.org/10.1371/journal.pgen.1009231.t004

VUS in DNA repair pathway genes (ATM, BLM, NBN, MLH1, MSH2, MSH6, ERCC4, FANCA/E/F/G/I/L, BRCA1, BRCA2, RAD51C, RFWD3, SLX4), 16/198 (8.1%) patients had a VUS in genes associated with bone marrow failure (RPL5, RPS10, RPS19, CTC1, DKC1, NHP2, PARN, RTEL1, TERT, SBDS), 12/198 (6.1%) patients had a VUS in the RAS pathway (CBL, NF1, A2ML1, MAP2K2, PTPN11, RAF1, RRAS, SHOC2), and nine of 198 (4.5%) patients had a VUS in genes associated with familial leukemia (ETV6, GATA2, IKZF1, RUNX1, PAX5). Thirty-eight of the 198 (19.2%) patients had a VUS in a gene previously associated with the cancer diagnosed in the child. When subgroups were separated by diagnoses, 30 of 105 (28.6%) patients with hematologic malignancies had a VUS in a relevant gene associated with childhood onset (A2ML1, ADA, ATM, BLM, BRCA2, CREBBP, DDX41, DNAJC21, EFL1, EP300, ERCC6L2, FANCF, MAP2K2, PARN, PAX5, PTPN11, RPL5, RRAS, SH2D2A, SHOC2, SOS2, TERT, TNFRSF13B). One of the 44 (2.3%) patients with central nervous system (CNS) tumors had a VUS in a gene predisposing to Fanconi Anemia in which childhood-onset brain tumors have been described (FANCG), and seven of the 49 (14.3%) patients with solid tumors had a VUS in a relevant gene associated with childhood onset (BRCA2, CDH23, EP300, *ERCC6L2*, *FANCI*, *RB1*, *RFWD3*, *XRCC2*). Most variants occurred in DNA repair pathway genes (S1 Data). Four patients had a VUS, but none had a PV, in a mismatch repair pathway gene.

Fulfillment of clinical criteria indicating an underlying CPS

All patients were evaluated using a phenotype checklist developed for this study (S1 Text), and 116/198 (58.6%) patients had one or more CPS-associated findings.

Overall, 70/198 (35.4%) patients fulfilled Jongmans' (n = 56, 28.3%) and/or MIPOGG criteria (n = 64, 32.3%) including 17 (81.0%) of the 21 patients with a childhood-onset CPS (Tables 8 and 9). Of the four patients with a PV in a childhood-onset CPS gene who did not fulfill Jongmans' criteria, none had excessive chemotherapy-induced toxicity. Patients not identified by either tool included two with PVs in *TP53*, and one with a pathogenic *SMARCA4* variant. The patient with a PV in *CDC73* was identifies by MIPOGG and not by Jongmans. The *SMARCA4*-deletion patient was diagnosed with synovial sarcoma of the ovary, revised to

Patient diagnosis	Gene	Variant	Protein	Family history					
Patients with childhood-onset CPS									
Acute myeloid leukemia	CDC73	c.358C>T	p.(Arg120*)	2 nd -degree relative (maternal side): grandfather: chronic lymphoblastic leukemia, 62 years					
Plasmacytoid dendritic cell leukemia	DDX41 DDX41	c.962C>T c.937G>C	p.(Pro321Leu) p.(Gly313Arg)	No cancer cases in 1 st -2 nd -degree relatives Sister: intellectual disability corresponding to the phenotype of the syndrome identified in this patient					
Osteosarcoma	LZTR1	c.955C>T	p.(Gln319*)	2 nd -degree relative (maternal side): grandfather: lymphoma, 68 years					
Optic nerve glioma	NF1	c.5242C>T	p.(Arg1748*)	No cancer cases in 1 st -2 nd -degree relatives					
Acute myeloid leukemia	NF1	c.288+1delG	p.(?)	No cancer cases in 1 st -2 nd -degree relatives					
Malignant peripheral nerve sheath tumor ¹	NF1	c.61-22171_4110+2458del (deletion of exon 2–30)	p. (Leu21_Gln1370del)	No cancer cases in 1 st -2 nd -degree relatives					
Pilocytic astrocytoma	NF1	c.2033dupC	p.(Ile679Aspfs*21)	2 nd -degree relative (maternal side): grandfather: colon cancer, 84 years					
Retinoblastoma	RB1	c.1735C>T	p.(Arg579*)	No cancer cases in 1 st -2 nd -degree relatives					
Retinoblastoma	RB1	c.409_412delGAAA	p.(Glu137Leufs*15)	1 st -degree relative: father, retinoblastoma, 0 years 2 nd -degree relatives (paternal side): father's sister: retinoblastoma (0 years), rhabdomyosarcoma (14 years), melanoma (20 years). Grandfather: melanoma (39 years), myelofibrosis (48 years)					
Retinoblastoma	RB1	c.219_220delAG	p.(Arg73Serfs*36)	No cancer cases in 1 st -2 nd -degree relatives					
Retinoblastoma	RB1	c.2663+2T>C	p.(?)	No cancer cases in 1 st -2 nd -degree relatives					
Acute promyelocytic leukemia	SDHC	c.148C>T	p.(Arg50Cys)	No cancer cases in 1 st -2 nd -degree relatives					
Small cell carcinoma	SMARCA4	c.2002-625_2124-1045del (Deletion of exon 14)	p.(Glu669Cysfs*7)	2 nd -degree relative (paternal side): grandfather: lung cancer, 71 years, (maternal side): grandfather: lung cancer, 79 years					
Precursor B-cell acute lymphoblastic leukemia	TP53	c.637C>G	p.(Arg213Gly)	 1st-degree relative: father: pheochromocytoma, 34 years (not diagnosed at the time of the child's diagnosis) 2nd-degree relative (paternal side): grandmother: hepatic cholangiocarcinoma, 36 years 					
Osteosarcoma	TP53	c.818G>A	p.(Arg273His)	2 nd -degree relative (paternal side): grandfather: colon cancer, 84 years					
Subependymal giant cell astrocytoma	TSC2	c.4141dupC	p.(Leu1382Profs*32)	2 nd -degree relative (maternal side): grandfather: urothelial carcinoma, 71 years					
Wilms tumor ²	Paternal un Beckwith–V	iparental disomy of chromosom Viedemann syndrome	e 11, corresponding to	2 nd -degree relatives (maternal side): grandmother: lung cancer, 64 years, mother's brother: urothelial carcinoma, 41 years					
Acute megakaryoblastic leukemia (two patients, twins)	47,XY,+21			2 nd -degree relative (paternal side): grandmother: lung cancer, 50 years					
Hodgkin lymphoma	47,XX,+21			2 nd -degree relatives (maternal side): grandmother: ovarian cancer, 68 years, (paternal side): grandmother: gastrointestinal stromal tumor, 82 years					
Precursor B-cell acute lymphoblastic leukemia	47,XX,+21			2 nd -degree relative: mother's sister: melanoma, 37 years					
Patients with adult-onset CPS									
Wilms tumor	APC	c.3920T>A	p.(Ile1307Lys)	2 nd -degree relative (paternal side): grandmother: urothelial carcinoma, 74 years					
Neuroblastoma	APC	c.3920T>A	p.(Ile1307Lys)	No cancer cases in 1 st -2 nd -degree relatives					
Rhabdomyosarcoma	ATM	c.9023G>C	p.(Arg3008Pro)	2 nd -degree relative (maternal side): mother's brother: tumor on heart valve,0 years					
Wilms tumor	BARD1	g.215591264-215774591 (Deletion of exon 1–11)	p.(?)	No cancer cases in 1 st -2 nd -degree relatives					
Langerhans cell histiocytosis	BRCA2 AXIN2	c.5722_5723delCT c.815+1G>A	p.(Leu1908Argfs*2) p.(?)	2 nd -degree relative (paternal side): grandfather: esophageal cancer, 59 years					

Table 5. Family history of patients with pathogenic and likely pathogenic variants in childhood-onset and adult-onset cancer genes.

(Continued)

Gene	Variant	Protein	Family history						
Patients with childhood-onset CPS									
BRCA2	c.6486_6489delACAA	p.(Lys2162Asnfs*5)	2 nd -degree relative (maternal side): grandmother: breast cancer, 63 years						
CHEK2	c.1100del	p.(Thr367Metfs*15)	2 nd -degree relatives (paternal side): grandfather: prostate cancer, 65 years, grandmother: cervical cancer, 54 years						
MUTYH	c.536A>G	p.(Tyr179Cys)	No cancer cases in 1 st -2 nd -degree relatives						
PALB2	c.2736G>A	p.(Trp912*)	No cancer cases in 1 st -2 nd -degree relatives						
	Gene BRCA2 CHEK2 MUTYH PALB2	Gene Variant Patients wit BRCA2 c.6486_6489delACAA CHEK2 c.1100del MUTYH c.536A>G PALB2 c.2736G>A	Gene Variant Protein Patients with childhood-onset CPS BRCA2 c.6486_6489delACAA p.(Lys2162Asnfs*5) CHEK2 c.1100del p.(Thr367Metfs*15) MUTYH c.536A>G p.(Tyr179Cys) PALB2 c.2736G>A p.(Trp912*)						

Table 5. (Continued)

¹Same patient carrying these two variants.

²Not identified by whole-genome sequencing.

https://doi.org/10.1371/journal.pgen.1009231.t005

small-cell carcinoma based on this study, and would have fulfilled both criteria if the initial diagnosis had been correct. Of the patients with adult-onset CPS, 2/9 (22.2%) fulfilled Jongmans' (n = 2) and MIPOGG (n = 1) criteria, which is significantly fewer than for childhood-onset CPS (p = 0.0022). Of the additional 23 patients with a heterozygous PV predisposing to biallelic CPS, eight (34.8%) fulfilled Jongmans' (n = 5) and MIPOGG (n = 7) criteria.

The number of VUS identified were higher among patients without a CPS and with adultonset CPS compared to patients with a childhood-onset CPS, in the first group patients on average carried 2.5 VUS compared to 1.6 VUS in the latter group. The same was the case when comparing patients with a childhood-onset CPS to patients who solely fulfilled Jongmans/ MIPOGGs criteria, patients carrying a childhood-onset CPS carried an average of 1.6 VUS compared to 2.5 VUS among patients fulfilling Jongmans/MIPOGGs criteria alone.

Family histories of cancer

Parents reported cancer diagnoses for 704 family members, 106 of whom resided outside Denmark, precluding further verification. Cancer diagnoses were verified for 328 (54.8%) of the remaining 598 family members, whereas the others did not consent to retrieval of medical records (n = 45) or their diagnoses could not be verified (n = 225) due to difficulties identifying distant/deceased family members or cancer occurrence prior to registration in Danish registries (before 1943). For 1st-, 2nd-, and 3rd-degree relatives 16 (100.0%), 133 (84.1%), and 179 (42.2%) cases were verified, respectively. The following is based on verified diagnoses and family recollection (for 1st to 3rd generation family members) when verification was impossible.

In total, 191/198 (96.5%) participants had a family history of cancer. Seven of 198 (3.5%) participants had a family member diagnosed with cancer before 18 years of age (two had a CPS). Fifty-six of 198 (28.3%) participants had at least one relative diagnosed with cancer between the ages of 18 and 45. Three of 198 (1.5%) participants had two or more relatives under the age of 45 diagnosed with cancer.

Forty-three of 198 (21.7%) participants had a relative with a cancer of the same organ system as the patient. Patients with hematologic malignancies and solid tumors did not have more family members with cancers of the same organ system than the other two patient groups. In contrast, patients with a CNS tumor had a family member with a malignancy in the CNS more frequently than patients with either solid tumors or hematologic malignancies (p = 0.04). This association also held (p = 0.04) when patients with a CPS were eliminated (Table 10). Family history for the patients with a confirmed CPS can be found in Table 5.

Diagnosis	Gene	Variant	Protein	CADD-PHRED score
Acute myeloid leukemia ¹	ADA	c.646G>A	p.(Gly216Arg)	28.0
Precursor B-cell acute lymphoblastic leukemia	ADA	c.1078+2T>A	p.(?)	22.9
Chronic myeloid leukemia	ATR	c.2320dupA	p.(Ile774Asnfs*3)	20.1
Rhabdomyosarcoma	EFL1	c.159+3A>G	p.(?)	14.84
Precursor T-cell acute lymphoblastic leukemia	EFL1	c.2430_2431delCC	p.(Leu811Asnfs*10)	15.9
Wilms tumor	ERCC3	c.1115_1120dupAGCAGT	p.(Trp374*)	37.0
Astrocytoma	FANCA	c.3482C>T	p.(Thr1161Met)	17.3
Precursor B-cell acute lymphoblastic leukemia	FANCA	c.3391A>G	p.(Thr1131Ala)	23.5
Acute myeloid leukemia	FANCC	c.535C>T	p.(Arg179*)	35.0
Yolk sac tumor	FANCE	c.108delG	p.(Pro37Leufs*47)	16.7
Precursor B-cell acute lymphoblastic leukemia	FANCI	c.158-5A>G	p.(?)	12.7
Precursor T-cell acute lymphoblastic leukemia	FANCL	c.540+1G>A	p.(?)	23.3
Precursor B-cell acute lymphoblastic leukemia	FANCL	c.1007_1009delTAT	p.(Ile336_Cys337delinsSer)	23.5
Lymphoma	FANCL	c.1096_1099dupATTA	p.(Thr367Asnfs*13)	35.0
Acute myeloid leukemia ¹	FANCM	c.681+1G>C	p.(?)	25.9
Rhabdomyosarcoma	FANCM	c.2156_2160delAACCA	p.(Lys719Serfs*15)	36.0
Plasmacytoid dendritic cell leukemia	NBN	c.156_157delTT	p.(Ser53Cysfs*8)	25.6
Wilms tumor	NBN	c.834dupA	p.(Gln279Serfs*6)	37.0
Precursor B-cell acute lymphoblastic leukemia	POLH	c.1600_1610delCA	p.(Gln534Glufs*11)	40.0
Precursor B-cell acute lymphoblastic leukemia	POLH	c.491-69_660+30del (deletion of exon 5)	p.(Glu164Glyfs*37)	-
Ganglioglioma	RECQL	c.1859C>G	p.(Ser620*)	38.0
Craniopharyngioma	RECQL	c.1859C>G	p.(Ser620*)	38.0
Precursor B-cell acute lymphoblastic leukemia	RECQL4	c.3072delA	p.(Val1026Cysfs*18)	21.7
Lymphoma	RINT1	c.88+3A>G	p.(?)	15.4
Glioma ²	TNFRSF13B	c.431C>G	p.(Ser144*)	35.0
Craniopharyngioma	WRAP53	c.1192C>T	p.(Arg398Trp)	34.0
Precursor B-cell acute lymphoblastic leukemia	WRAP53	c.1192C>T	p.(Arg398Trp)	34.0
Neurofibroma	XPC	c.1934delC	p.(Pro645Leufs*5)	26.6

Table 6. Patients with pathogenic or likely pathogenic variants in biallelic cancer predisposition genes.

Three of the patients listed above also had a monoallelic pathogenic germline mutation (fam no. 13, 25 and 51).

Monoallelic variants in RECQL are pathogenic; however, their relationship to cancer is uncertain. Therefore, they are listed here.

¹Same patient carrying the ADA and FANCM variants.

²Pathogenic variants (Romberg *et al.*, 2013) may be inherited via an autosomal dominant or autosomal recessive. pattern. Based on the patient's phenotype, this variant was considered inherited recessively.

https://doi.org/10.1371/journal.pgen.1009231.t006

Secondary findings

Two patients had PVs in genes associated with familial hypercholesterolemia (*APOB* and *LDLR*), three had PVs in genes associated with arrhythmic right ventricular cardiomyopathy (*DSC2*, *DSG2*, and *PKP2*), and one patient had a PV in *KCNQ1*, which is associated with long QT syndrome. These six variants are associated with increased risk of disease and families were informed. Overall, 18 patients (9.1%) had an ACMG 'actionable' PV, including 12 PVs in CPS genes and six PVs in genes associated with other non-malignant diseases (Table 11).

Discussion

In this first nationwide unselected cohort of consecutive pediatric cancer patients, half had a likely or validated underlying CPS, based on WGS, clinical examination, and pedigree

Diagnosis of the patient	Gene	Variant	Protein	Gene	Variant	Protein	Gene	Variant	Protein
Malignant peripheral nerve sheath tumor	NF1	c.61-22171_4110 +2458del (deletion of exon 2–30)	p. (Leu21_Gln1370del)	PALB2	c.2736G>A	p.(Trp912*)	-	-	-
Optic nerve glioma	NF1	c.5242C>T	p.(Arg1748*)	XPC	c.1934delC	p. (Pro645Leufs*5)	-	-	-
B-cell acute lymphoblastic leukemia	47,XX,+21			POLH	c.1600_1610delCA	p. (Gln534Glufs*11)	-	-	-
Plasmacytoid dendritic cell leukemia	DDX41	c.962C>T	p.(Pro321Leu)	DDX41	c.937G>C	p.(Gly313Arg)	NBN	c.834dupA	p. (Gln279Serfs*6)
Wilms tumor	BARD1	g.215591264- 215774591 (deletion of exon 1–11)	p.(?)	ERCC3	c.1115_1120dupAGCAGT	p.(Trp374*)	-	-	-
Langerhans cell histiocytosis	BRCA2	c.5722_5723delCT	p.(Leu1908Argfs*2)	AXIN2	c.815+1G>A	p.(?)	-	-	-
Acute myeloid leukemia	ADA	c.646G>A	p.(Gly216Arg)	FANCM	c.681+1G>C	p.(?)	-	-	-

Table 7. Patients carrying more than one pathogenic/likely pathogenic variant.

https://doi.org/10.1371/journal.pgen.1009231.t007

mapping, and 14.6% had a genetically verified CPS. These findings strongly indicate that genetic predisposition to childhood cancer may be far more common than previously supposed. Furthermore, other modes of inheritance (di-, oligo- and polygenic risk) may play significant roles in pathogenesis.

Our childhood-onset CPS results are consistent with previous studies that found a CPS in 7–10% of pediatric cancer patients.[8–11]

The frequency of PVs in our study was significantly higher than that observed in control cohorts wherein 0.6-1.1% of adult patients in a Genomics England cohort and a cohort of pediatric and adult patients with autism had PVs in CPS genes.^[7] This study, however, excluded patients with known CPS and included different genes (including genes with frequent somatic variants) and is thus not directly comparable. A study of osteosarcoma patients found a remarkably high frequency of CPSs in control cohorts (12.1% and 9.3%), probably because many of the genes included (e.g., PMS1, and COL7A1) were not definitely linked to cancer.[6] Other studies have included adult-onset CPS genes. For example, Zhang et al. found only 0.7% of their patients carried an adult-onset CPS variant (BRCA1/2 and PALB2).[7] We found that 1.5% of our patients carried PVs in BRCA2 and PALB2. Interestingly, another Scandinavian study reported a significantly higher prevalence of childhood cancer in families with PVs in BRCA2.[40] Similarly, Wilson et al. showed that BRCA2 was one of the most frequently mutated genes among childhood cancer survivors.[11] Therefore, BRCA2 variants may be important in childhood cancer etiology, [40] potentially influencing treatment options if deficiencies in homologous repair promote some tumors. Even though a higher frequency of PVs in *BRCA2* than *BRCA1* have been found in the general population^[41], this does not explain why multiple studies have identified so few PVs in *BRCA1*, which, in the Danish population, are more frequently associated with breast cancer than PVs in BRCA2.[42,43] Overall, WGS data from ethnically comparable children are lacking making comparisons of genetic findings in patients difficult. As most children survive cancer; therefore, identifying adult-onset CPSs is important for future surveillance and counselling.

Diagnosis (patient ID)	CPS (gene)	Jongmans	MIPOGG
Precursor B-cell acute lymphoblastic leukemia (A1)	Li–Fraumeni syndrome (<i>TP53</i>)	-	-
Osteosarcoma (A2)	Li-Fraumeni syndrome (TP53)	-	-
Acute promyelocyte leukemia (B1)	Familial paraganglioma and pheochromocytoma syndrome (SDHC)	+	+
Acute myeloid leukemia (C1)	Hyperparathyroidism-Jaw tumor syndrome (CDC73)	-	+
Acute myeloid leukemia (E1)	Neurofibromatosis type 1 (NF1)	+	+
Malignant peripheral nerve sheath tumor ¹ (E2)	Neurofibromatosis type 1 (NF1)	+	+
Optic nerve glioma (E3)	Neurofibromatosis type 1 (NF1)	+	+
Pilocytic astrocytoma (E4)	Neurofibromatosis type 1 (NF1)	+	+
Osteosarcoma (F1)	Schwannomatosis/Noonan syndrome (LZTR1)	+	+
Plasmacytoid dendritic cell leukemia (G1)	Novel putative childhood leukemia cancer predisposition syndrome (biallelic <i>DDX41</i>)	+	+
Retinoblastoma (H1)	Familial retinoblastoma syndrome (RB1)	+	+
Retinoblastoma (H2)	Familial retinoblastoma syndrome (RB1)	+	+
Retinoblastoma (H3)	Familial retinoblastoma syndrome (RB1)	+	+
Retinoblastoma (H4)	Familial retinoblastoma syndrome (RB1)	+	+
Wilms tumor (I1)	Beckwith-Wiedemann syndrome (pUPD chr 11)	+	+
Subependymal giant cell astrocytoma (J1)	Tuberous sclerosis complex (TSC2)	+	+
Small cell carcinoma of the ovary (K1)	Rhabdoid tumor predisposition syndrome (SMARCA4)	-	-
Acute myeloid leukemia (L1)	Down syndrome (46,XY+21)	+	+
Acute myeloid leukemia (L2)	Down syndrome (46,XY+21)	+	+
Hodgkin lymphoma (L3)	Down syndrome (46,XX+21)	+	+
Precursor B-cell acute lymphoblastic leukemia (L4)	Down syndrome (46,XX+21)	+	+
Total number of patients with childhood	d cancer predisposition syndrome	17/21 = 80.9%	18/21 = 85.7%
Precursor B-cell acute lymphoblastic leukemia (M1)	MUTYH-associated polyposis (MUTYH)	-	-
T-cell acute lymphoblastic leukemia (N1)	Familial breast and ovarian cancer (BRCA2)	-	-
T-cell acute lymphoblastic leukemia (O1)	Familial breast cancer (<i>CHEK2</i>)	-	-
Langerhans cell histiocytosis (N2)	Familial breast and ovarian cancer (<i>BRCA2</i>), oligodontia- colorectal cancer syndrome (<i>AXIN2</i>)	-	-
Malignant peripheral nerve sheath tumor ¹ (P1)	Familial breast and ovarian cancer (PALB2)	+ (fulfills due to <i>NF1</i> variant, not counted below)	+ (fulfills due to <i>NF1</i> variant)
Neuroblastoma (Q1)	Familial adenomatous polyposis (APC)	+	-
Wilms tumor (Q2)	Familial adenomatous polyposis (APC)	+	+
Rhabdomyosarcoma (R1)	Ataxia telangiectasia (ATM)	-	-
Wilms tumor (S1)	Familial breast and ovarian cancer and familial neuroblastoma (BARD1)	-	-
Total number of patients with adult-ons	et cancer predisposition syndrome	2/9 = 22.2%	1/9 = 11.1%

Table 8.	Patients with an	underlvin	g cancer p	redisposit	ion syndrome	e according to	Iongmans'	and MIPOGG criteria
rable of	I actentes witch an	anacitym	s cuncer p	reallop 0010	ion synaronic	c accoranic to	Joinginano	

+ fulfills the criteria,-does not fulfill the criteria.

¹same patient carrying these variants, patient not counted in the adult-onset cancer predisposition syndrome.

Red: childhood cancer predispositions syndrome, Blue: adult-onset cancer predisposition syndrome.

https://doi.org/10.1371/journal.pgen.1009231.t008

Table 9. Phenotypes identified using Jongmans'/MIPOGG criteria.

Non-cancer diagnosis	Phenotypic finding	Genetic findings
Autism spectrum disorder	developmental delay, speech delay, learning difficulties	Klinefelter syndrome
Autism spectrum disorder	developmental delay, learning difficulties	-
Autism spectrum disorder	developmental delay (does not speak until age four), learning difficulties, strabismus	-
Autism spectrum disorder	developmental delay (speech delay), learning difficulties	-
Down syndrome	intellectual disability, epicanthus, strabismus, developmental delay, single palmar crease	47,XY,+21
Down syndrome	intellectual disability, epicanthus, strabismus, developmental delay, single palmar crease	47,XY,+21
Down syndrome	intellectual disability, epicanthus, strabismus, developmental delay, single palmar crease	47,XX,+21
Down syndrome	intellectual disability, epicanthus, strabismus, flat- footed, hearing deficit	47,XX,+21 POLH, c.1600_1610delCA, p. (Gln534Glufs*11)
Neurofibromatosis type 1	multiple café-au-lait spots	<i>NF1</i> , c.288+1delG, p.(?)
Neurofibromatosis type 1	multiple café-au-lait spots	<i>NF1</i> , c.5242C>T, p.(Arg1748*) <i>XPC</i> , c.1934delC, p.(Pro645Leufs*5)
Neurofibromatosis type 1	multiple café-au-lait spots hearing deficits left ear	<i>NF1</i> , c.61-22171_4110+2458del (deletion of exon 2–30), p.(Leu21_Gln1370del) <i>PALB2</i> , c.2736G>A, p.(Trp912*)
Neurofibromatosis type 1	multiple café-au-lait spots near-sightedness	<i>NF1</i> , c.2033dupC, p.(Ile679Aspfs21)
Tuberous sclerosis	intellectual disability, hypomelanotic macules, seizures	<i>TSC2</i> , c.4141dupC, p.(Leu1382Profs*32)
Goldenhar syndrome, craniofacial microsomia	mild phenotype with skintags in front of both ears, lack of iris coloring in part of the right eye	<i>EFL1</i> , c.2430_2431delCC, p. (Leu811Asnfs*10) (no genes are known to cause Goldenhar syndrome)
Behcet's disease	frequent mucocutaneous ulcerations, hyperpigmentation of the lower back	– (tissue type: HLA-B7)
Suspicion of Charcot–Marie–Tooth, but no definite molecular genetic diagnosis	strabismus, delayed motor development, hypotonia, hyperpigmentation of the head and legs, severe vincristine toxicity. Mother has a form of skeletal dysplasia with short fingers and arms, extensions defect in the elbow joint, flat feet	SH3TC2, c.279G>A (AR) KIF1B, c.3401CT, p.(Pro1134Leu) (VUS, parental testing planned)
Beckwith-Wiedemann syndrome	epicanthus, down slanting palpebrae, hypertelorism, macroglossia, overgrowth	Paternal uniparental disomy of chromosome 11, corresponding to Beckwith–Wiedemann syndrome phenotype
Novel childhood predisposition syndrome associated with leukemia and intellectual disability	macroglossia, poor mouth motor skills, small milk teeth, deformed fingers and toes, hypotonia	DDX41, c.962C>T, p.(Pro321Leu) DDX41, c.937G>C, p.(Gly313Arg) NBN, c.156_157delTT, p.(Ser53Cysfs*8)
No genetic diagnosis	deeply set eyes, hypertelorism, large café-au-lait spots, right leg	-
No genetic diagnosis	severe speech delay–speech not understandable age 5 years, macrocephaly	-
	Non-cancer diagnosisAutism spectrum disorderAutism spectrum disorderAutism spectrum disorderAutism spectrum disorderDown syndromeDown syndromeDown syndromeDown syndromeNeurofibromatosis type 1Neurofibromatosis type 1Neurofibromatosis type 1SelerosisGoldenhar syndrome, craniofacial microsomiaBehcet's diseaseSuspicion of Charcot-Marie-Tooth, but no definite molecular genetic diagnosisNovel childhood predisposition syndrome associated with leukemia and intellectual disabilityNo genetic diagnosis	Non-cancer diagnosisPhenotypic findingAutism spectrum disorderdevelopmental delay, speech delay, learning difficultiesAutism spectrum disorderdevelopmental delay (law of speak until age four), learning difficulties, strabismusAutism spectrum disorderdevelopmental delay (speech delay), learning difficultiesAutism spectrum disorderdevelopmental delay (speech delay), learning difficultiesDown syndromeintellectual disability, epicanthus, strabismus, developmental delay, single palmar creaseDown syndromeintellectual disability, epicanthus, strabismus, flat- footed, hearing deficitNeurofibromatosis type 1multiple café-au-lait spotsNeurofibromatosis type 1multiple café-au-lait spots near-sightednessIderous sclerosisintellectual disability, hypomelanotic macules, seizuresGoldenhar syndrome, craniofacial microsomiamid phenotype with skintags in front of both ears, lack of iris coloring in part of the right eyeSuspicion of Charcot-Marie-Tooth, but no definite molecular genetic diagnosisstrabismus, delayed motor development, hypotonia, hyperpigmentation of the lower back.Novel childhood predisposition syndrome associate

- No relevant genetic variants.

https://doi.org/10.1371/journal.pgen.1009231.t009

Many of our patients carried PVs in genes involved in DNA repair. Children have high celldivision rates, and deficiencies in DNA repair may result in accumulation of DNA damage and ultimately cancer. Fanconi anemia (FA) is associated with many large genes, and the

Table 10.	Family	pedigree	findings	for 1st-3rd	degree relatives.
-----------	--------	----------	----------	-------------	-------------------

	All patients, n (%)	Patients with pathogenic/likely pathogenic variant in cancer predisposition gene, $n (\%)^1$
Malignancies in family members <18 years	7 (3.5%)	2 (6.9%)
Relatives with cancer aged 18-45 years	55 (27.8%)	9 (31.0%)
Two or more 1 st - or 2 nd -degree relatives in the same parental lineage with cancer <45 years	4 (2.0%)	1 (3.4%)
Any cancer history in the family	189 (95.5%)	29 (100.0%)
More than one family member with cancer	174 (87.9%)	28 (96.6%)
Any family member with cancer of the same organ as the patient	33 (16.7%)	7 (24.1%)
Any family member with a hematologic malignancy - To a child with a hematologic tumor - To a child with a CNS tumor - To a child with a solid tumor	43 (21.7%) 25 (23.8%) 8 (18.2%) 10 (20.4%)	9 (31.0%)
Any family member with a CNS tumor - a child with a hematologic tumor - To a child with a CNS tumor - To a child with a solid tumor	25 (12.6%) 9 (8.6%) 11 (25.0%) 5 (10.2%)	2 (6.9%)
Any family member with a solid tumor (defined as any kidney tumor, retinoblastoma, bone tumor, neuroendocrine tumors, gastrointestinal stromal tumor, or rhabdomyosarcoma) - To a child with a hematologic tumor - To a child with a CNS tumor - To a child with a solid tumor	27 (13.6%) 14 (13.3%) 6 (13.6%) 7 (14.3%)	7 (24.1%)
Chi2 test for differences between the groups	<i>p</i> = 0.04	
Any family member with breast cancer Two or more family members with breast cancer	76 (38.4%) 29 (14.6%)	11 (37.9%) 2 (6.9%)
Any family member with any gastrointestinal cancer Two or more family members with any gastrointestinal cancer	74 (37.4%) 20 (10.1%)	12 (41.4%) 4 (13.8%)

¹Percentages are fractions of the 29 patients with a cancer predisposition syndrome.

https://doi.org/10.1371/journal.pgen.1009231.t010

frequency of PVs in FA genes was 4.3% in an adult population of 7,578 patients from the Exome Sequencing Project and the 1000 Genomes Project.[44] This is consistent with our results, which showed that 13 (6.6%) patients carried a PV in a FA gene. Pathogenic FA variants are associated with a small increase in lifetime adult-onset cancer risk,[45–47] and this may also be true for childhood-onset CPS.

Phenotype	Diagnosis	Gene/chromosomal alteration	Variant	Protein	Events corresponding to carrier status
Familial hypercholesterolemia	Burkitt lymphoma	АРОВ	c.1013delC	p. (Gln3378Hisfs*4)	-
Familial hypercholesterolemia	Glioma	LDLR	c.409G>A	p.(Gly137Ser)	-
Arrhythmogenic right ventricular cardiomyopathy	Diffuse intrinsic pontine glioma	РКР2	c.1643delG	p. (Gly548Valfs*15)	-
Arrhythmogenic right ventricular cardiomyopathy	Precursor B-cell acute lymphoblastic leukemia	DSC2	c.2508 +5G>A	p.(?)	-
Arrhythmogenic right ventricular cardiomyopathy	Glioma	DSG2	c.918G>A	p.(Trp306*)	-
Romano–Ward long QT syndrome	Anaplastic large-cell lymphoma	KCNQ1	c.905C>T	p.(Ala302Val)	Cardiac arrest during treatment, attributed to large tumor in thorax and subsequent mecha- nical obstruction

- No known clinical events

https://doi.org/10.1371/journal.pgen.1009231.t011

Interestingly, we observed one *CDC73* VUS and one PV in two patients with hematologic malignancies. PVs in *CDC73* cause 'hyperparathyroidism-jaw tumor syndrome' and parathyroid carcinoma,[48] and have been linked with hematologic cancer in mouse models.[49] RNA sequencing of leukemic cells from these patients showed no LOH, making a causal association less likely but not impossible.[50] Furthermore, we identified two patients with heterozygous deleterious variants in *ERCC6L2*, a gene linked to a bone marrow failure syndrome. [51] These patients were diagnosed with T-lineage acute lymphoblastic leukemia (ALL) and rhabdomyosarcoma, respectively. Tumor tissue was not available for further investigation.

Seven patients had more than one PV in CPS genes, suggesting that di-, oligo-, and polygenic inheritance can cause predisposition to childhood cancer. Four of these patients exhibited the phenotype associated with the childhood-onset PV. Bioinformatic predictions suggested that pathogenicity was highly likely in one of the seven patients. Other studies have also found more than one PV in the same patient, suggesting that digenic/polygenic inheritance may play a role in childhood cancer etiology,[8,52,53] as *MUTYH* and *OGG1* do in colorectal cancer etiology.[54] Kuhlen *et al.*[55] proposed a model of concomitant digenic inheritance involving two PVs within the same pathway combining to increase the likelihood of disease development. Generally, the observations from this and other studies suggest that the risk of disease development may increase by having more than one PV, even if the corresponding genes function in different pathways.

PVs in genes not previously associated with cancer development were identified. Some of these genes were 'actionable' and their identities were disclosed to the children's families, in accordance with ACMG recommendations. It is important to identify genes associated with increased risk of cardiac disease in pediatric cancer patients due to the increased risk of both cardiomyopathy[56] and symptoms in patients with long QT syndrome[57] undergoing anti-cancer treatment. PVs in these genes may also have clinical implications for family members.

We applied Jongmans' and MIPOGG criteria to assess the risk of underlying childhood CPSs. The majority of patients (85.7%) with a childhood-onset CPS were identified using these criteria. However, among the three unidentified patients were the two with Li-Fraumeni syndrome (one with ALL and one with osteosarcoma). Li-Fraumeni syndrome is associated with a high lifetime-risk of cancer, and the risk of a secondary cancer is further increased when the first cancer occurs during childhood.[58,59] Data suggest that surveillance programs for Li-Fraumeni patients increase their survival rates.[60] However, in contrast to other studies, patients with Li-Fraumeni syndrome were not identified here.[8,16] A possible explanation is that one of our patients carried a de novo TP53 variant that could not be identified from a family history of cancer. Additionally, CPSs that are not associated with syndromic features may not fulfill relevant criteria and will be difficult to identify if the cancer is not pathognomonic of the CPS. Family history was only rarely the cause of fulfillment of Jongmans'/MIPOGG criteria in both patients with childhood- and adult-onset CPS. The primary causes of fulfillment of Jongmans'/MIPOGG criteria were the patient's diagnosis and clinical characteristics. This is interesting as family history is believed to be highly indicative of adult-onset CPS like hereditary breast- and ovarian cancer and Lynch syndrome. A possible explanation for this could be that more variants are *de novo* in pediatric cancer patients and that the age of pediatric cancer patient's parents is lower than parents of adult cancer patients.

We found that a family history of CNS tumors was associated with the case of childhood CNS tumors. However, only two of 44 patients with a CNS tumor carried a germline variant (*TSC2*, *NF1*), and none of these two patients had a $1^{st}-3^{rd}$ -degree family member with a CNS tumor. Therefore, there may be unidentified predisposition genes among CNS tumor patients. However, recall bias cannot be excluded, because CNS tumors among family members might be more memorable, especially if a child is diagnosed with a CNS tumor.

One limitation of this study is the lack of a comparison cohort, because population-based WGS data from ethnically comparable children are not publicly available. Another problem is whether PVs in cancer genes of children with cancers that are unassociated with that particular gene have occurred randomly. Other studies have found similar cases, in which the genotype and phenotype were not previously reported, [4,8] and it remains uncertain whether PVs in adult CPSs are driver or passenger mutations.[5,61] Thus, a large international collection of cases should be investigated to describe the phenotypic spectrum associated with each CPS variant.

Strengths of our study include the national setup with a consecutive cohort of unselected pediatric cancer patients, in-depth clinical examinations of children with cancer, and use of national databases to verify cancer diagnoses in family members. Additionally, we performed WGS instead of WES or gene panel analyses so that large structural rearrangements and CNVs could be identified, if present. Moreover, WGS will facilitate future analyses of deep intronic variants that affect splicing, variants within putative regulatory areas, and novel CPS genes.

These results demonstrate the value of systematically screening pediatric cancer patients for CPSs and strongly indicate that a higher proportion of childhood cancers may be linked to predisposing germline variants than previously supposed.

Supporting information

S1 Data. Gene panel and List of Variants of Unknown Significance (VUS). Gene panel outlining the 314 genes examined in each patient included in this study. List outlining all the VUS (CADD-PHRED score >20 and allele frequency <1%) found in the patients included in this study.

(XLSX)

S1 Text. Clinical checklist used in the clinical examination of all patient. (DOCX)

Acknowledgments

We should like to acknowledge the research nurses in all Pediatric Oncology Departments in Denmark, they were instrumental in making this study possible.

Author Contributions

Conceptualization: Kjeld Schmiegelow, Karin Wadt.

- **Data curation:** Anna Byrjalsen, Thomas V. O. Hansen, Anne–Marie Gerdes, Kjeld Schmiegelow, Karin Wadt.
- Formal analysis: Anna Byrjalsen, Thomas V. O. Hansen, Mana M. Mehrjouy, Karin Wadt.
- Funding acquisition: Anna Byrjalsen, Ulrik K. Stoltze, Rasmus L. Marvig, Anne–Marie Gerdes, Kjeld Schmiegelow, Karin Wadt.
- **Investigation:** Anna Byrjalsen, Lisa L. Hjalgrim, René Mathiasen, Charlotte K. Lautrup, Pernille A. Gregersen, Henrik Hasle, Peder S. Wehner, Ruta Tuckuviene, Maria Rossing, Rasmus L. Marvig, Niels Tommerup, Tina Elisabeth Olsen, David Scheie, Kjeld Schmiegelow, Karin Wadt.

Project administration: Kjeld Schmiegelow, Karin Wadt.

Software: Ulrik K. Stoltze, Nanna Moeller Barnkob, Peter Wad Sackett, Adrian O. Laspiur, Ramneek Gupta, Karin Wadt.

Supervision: Anne-Marie Gerdes, Kjeld Schmiegelow, Karin Wadt.

Writing - original draft: Anna Byrjalsen.

Writing - review & editing: Anna Byrjalsen.

References

- Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127:2893–2917. <u>https://doi.org/10.1002/ijc.25516</u> PMID: 21351269
- Volk J, Heck JE, Schmiegelow K, Hansen J. Parental occupational organic dust exposure and selected childhood cancers in Denmark 1968–2016. Cancer Epidemiol. 2020; 65:101667. <u>https://doi.org/10.1016/j.canep.2020.101667</u> PMID: 31955038
- Kirkeleit J, Riise T, Bjørge T, Christiani DC, Bråtveit M, Baccarelli A, et al. Maternal exposure to gasoline and exhaust increases the risk of childhood leukaemia in offspring–a prospective study in the Norwegian Mother and Child Cohort Study. Br J Cancer. 2018; 119:1028–1035. <u>https://doi.org/10.1038/</u> s41416-018-0295-3 PMID: 30318517
- Parsons DW, Roy A, Yang Y, Wang T, Scollon S, Bergstrom K, et al. Diagnostic yield of clinical tumor and germline whole-exome sequencing for children with solid tumors. JAMA Oncol. 2016; 2:616–624. https://doi.org/10.1001/jamaoncol.2015.5699 PMID: 26822237
- Waszak SM, Northcott PA, Buchhalter I, Robinson GW, Sutter C, Groebner S, et al. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. 2019; 19:785–798. <u>https://doi.org/10.1016/S1470-2045(18)30242-0</u> PMID: 29753700
- Mirabello L, Zhu B, Koster R, Karlins E, Dean M, Yeager M, et al. Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in Patients With Osteosarcoma. JAMA Oncol. 2020. https:// doi.org/10.1001/jamaoncol.2020.0197 PMID: 32191290
- Zhang J, Walsh MF, Wu G, Edmonson MN, Gruber TA, Easton J, et al. Germline Mutations in Predisposition Genes in Pediatric Cancer. N Engl J Med. 2015; 373:2336–2346. <u>https://doi.org/10.1056/</u> NEJMoa1508054 PMID: 26580448
- Chan SH, Chew W, Ishak NDB, Lim WK, Li ST, Tan SH, et al. Clinical relevance of screening checklists for detecting cancer predisposition syndromes in Asian childhood tumours. npj Genomic Med. 2018; 3:30. https://doi.org/10.1038/s41525-018-0070-7 PMID: 30455982
- Mody RJ, Wu YM, Lonigro RJ, Cao X, Roychowdhury S, Vats P, et al. Integrative clinical sequencing in the management of refractory or relapsed cancer in youth. JAMA—J Am Med Assoc. 2015; 314:913– 925. https://doi.org/10.1001/jama.2015.10080 PMID: 26325560
- Gröbner SN, Worst BC, Weischenfeldt J, Buchhalter I, Kleinheinz K, Rudneva VA, et al. The landscape of genomic alterations across childhood cancers. Nature. 2018; 555:321–327. <u>https://doi.org/10.1038/nature25480 PMID</u>: 29489754
- Wilson CL, Wang Z, Liu Q, Ehrhardt MJ, Mostafavi R, Easton J, et al. Estimated number of adult survivors of childhood cancer in United States with cancer-predisposing germline variants. Pediatr Blood Cancer. 2020; 67:e28047. https://doi.org/10.1002/pbc.28047 PMID: 31736278
- Gambale A, Russo R, Andolfo I, Quaglietta L, De Rosa G, Contestabile V, et al. Germline mutations and new copy number variants among 40 pediatric cancer patients suspected for genetic predisposition. Clin Genet. 2019; 96:359–365. https://doi.org/10.1111/cge.13600 PMID: 31278746
- Jongmans MCJ, Loeffen JLCM, Waanders E, Hoogerbrugge PM, Ligtenberg MJL, Kuiper RP, et al. Recognition of genetic predisposition in pediatric cancer patients: An easy-to-use selection tool. Eur J Med Genet. 2016; 59:116–125. https://doi.org/10.1016/j.ejmg.2016.01.008 PMID: 26825391
- Ripperger T, Bielack SS, Borkhardt A, Brecht IB, Burkhardt B, Calaminus G, et al. Childhood cancer predisposition syndromes—A concise review and recommendations by the Cancer Predisposition Working Group of the Society for Pediatric Oncology and Hematology. Am J Med Genet Part A. 2017; 173:1017–1037. https://doi.org/10.1002/ajmg.a.38142 PMID: 28168833
- Postema FA, Hopman SM, De Borgie CAJM, Hammond P, Hennekam RC, Merks JH, et al. Validation of a clinical screening instrument for tumour predisposition syndromes in patients with childhood cancer (TuPS): Protocol for a prospective, observational, multicentre study. BMJ Open. 2017; 7:e013237. https://doi.org/10.1136/bmjopen-2016-013237 PMID: 28110285

- Brozou T, Taeubner J, Velleuer E, Dugas M, Wieczorek D, Borkhardt A, et al. Genetic predisposition in children with cancer–affected families' acceptance of Trio-WES. Eur J Pediatr. 2018; 177:53–60. https://doi.org/10.1007/s00431-017-2997-6 PMID: 28929227
- Goudie C, Coltin H, Witkowski L, Mourad S, Malkin D, Foulkes WD. The McGill Interactive Pediatric OncoGenetic Guidelines: An approach to identifying pediatric oncology patients most likely to benefit from a genetic evaluation. Pediatr Blood Cancer. 2017; 64. <u>https://doi.org/10.1002/pbc.26441</u> PMID: 28097779
- Goudie C, Cullinan N, Villani A, Mathews N, van Engelen K, Malkin D, et al. Retrospective evaluation of a decision-support algorithm (MIPOGG) for genetic referrals for children with neuroblastic tumors. Pediatr Blood Cancer. 2018; 65:e27390. https://doi.org/10.1002/pbc.27390 PMID: 30117275
- Kalia SS, Adelman K, Bale SJ, Chung WK, Eng C, Evans JP, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): A policy statement of the American College of Medical Genetics and Genomics. Genet Med. 2017; 19:249–255. https://doi.org/10.1038/gim.2016.190 PMID: 27854360
- Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009; 25:1754–1760. https://doi.org/10.1093/bioinformatics/btp324 PMID: 19451168
- Tischler G, Leonard S. Biobambam: Tools for read pair collation based algorithms on BAM files. Source Code for Biology and Medicine. BioMed Central Ltd.; 2014. p. 13. https://doi.org/10.1186/1751-0473-9-13
- 22. Van der Auwera GA, Carneiro MO, Hartl C, Poplin R, del Angel G, Levy-Moonshine A, et al. From fastQ data to high-confidence variant calls: The genome analysis toolkit best practices pipeline. Curr Protoc Bioinforma. 2013. https://doi.org/10.1002/0471250953.bi1110s43 PMID: 25431634
- Chen X, Schulz-Trieglaff O, Shaw R, Barnes B, Schlesinger F, Källberg M, et al. Manta: Rapid detection of structural variants and indels for germline and cancer sequencing applications. Bioinformatics. 2016; 32:1220–1222. https://doi.org/10.1093/bioinformatics/btv710 PMID: 26647377
- Talevich E, Shain AH, Botton T, Bastian BC. CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing. PLoS Comput Biol. 2016; 12:e1004873. <u>https://doi.org/10.1371/journal.pcbi.1004873 PMID: 27100738</u>
- den Dunnen JT, Dalgleish R, Maglott DR, Hart RK, Greenblatt MS, Mcgowan-Jordan J, et al. HGVS Recommendations for the Description of Sequence Variants: 2016 Update. Hum Mutat. 2016; 37:564– 569. https://doi.org/10.1002/humu.22981 PMID: 26931183
- Rahman N. Realizing the promise of cancer predisposition genes. Nature. Nature Publishing Group; 2014. pp. 302–308. https://doi.org/10.1038/nature12981 PMID: 24429628
- Kircher M, Witten DM, Jain P, O'roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014; 46:310–315. https://doi.org/10. 1038/ng.2892 PMID: 24487276
- Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015; 17:405–424. https://doi.org/10.1038/gim.2015.30 PMID: 25741868
- Renaux A, Papadimitriou S, Versbraegen N, Nachtegael C, Boutry S, Nowé A, et al. ORVAL: a novel platform for the prediction and exploration of disease-causing oligogenic variant combinations. Nucleic Acids Res. 2019; 47:W93–W98. https://doi.org/10.1093/nar/gkz437 PMID: 31147699
- Bache I, Wadt K, Mehrjouy MM, Rossing M, Østrup O, Byrjalsen A, et al. A shared somatic translocation involving CUX1 in monozygotic twins as an early driver of AMKL in Down syndrome. Blood Cancer Journal. Springer Nature; 2020. p. 27. https://doi.org/10.1038/s41408-020-0293-6 PMID: 32127516
- Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: Results from prospective analysis of EMBRACE. J Natl Cancer Inst. 2013; 105:812– 822. https://doi.org/10.1093/jnci/djt095 PMID: 23628597
- 32. Yang X, Leslie G, Doroszuk A, Schneider S, Allen J, Decker B, et al. Cancer risks associated with germline PALB2 pathogenic variants: An international study of 524 families. J Clin Oncol. 2020; 38:674–685. https://doi.org/10.1200/JCO.19.01907 PMID: 31841383
- Mazzoni SM, Fearon ER. AXIN1 and AXIN2 variants in gastrointestinal cancers. Cancer Letters. Elsevier Ireland Ltd; 2014. pp. 1–8. https://doi.org/10.1016/j.canlet.2014.09.018 PMID: 25236910
- 34. Leshno A, Shapira S, Liberman E, Kraus S, Sror M, Harlap-Gat A, et al. The APC I1307K allele conveys a significant increased risk for cancer. Int J Cancer. 2016; 138:1361–1367. <u>https://doi.org/10.1002/ijc. 29876 PMID: 26421687</u>

- Goldgar DE, Healey S, Dowty JG, Da Silva L, Chen X, Spurdle AB, et al. Rare variants in the ATM gene and risk of breast cancer. Breast Cancer Res. 2011; 13. https://doi.org/10.1186/bcr2919 PMID: 21787400
- Couch FJ, Shimelis H, Hu C, Hart SN, Polley EC, Na J, et al. Associations between cancer predisposition testing panel genes and breast cancer. JAMA Oncol. 2017; 3:1190–1196. https://doi.org/10.1001/jamaoncol.2017.0424 PMID: 28418444
- Schmidt MK, Hogervorst F, Van Hien R, Cornelissen S, Broeks A, Adank MA, et al. Age-And tumor subtype-specific breast cancer risk estimates for CHEK2*1100delC Carriers. J Clin Oncol. 2016; 34:2750– 2760. https://doi.org/10.1200/JCO.2016.66.5844 PMID: 27269948
- Jones N, Vogt S, Nielsen M, Christian D, Wark PA, Eccles D, et al. Increased Colorectal Cancer Incidence in Obligate Carriers of Heterozygous Mutations in MUTYH. Gastroenterology. 2009; 137. https:// doi.org/10.1053/j.gastro.2009.04.047 PMID: 19394335
- Diness BR, Risom L, Frandsen TL, Hansen B, Andersen MK, Schmiegelow K, et al. Putative new childhood leukemia cancer predisposition syndrome caused by germline bi-allelic missense mutations in DDX41. Genes Chromosom Cancer. 2018; 57:670–674. https://doi.org/10.1002/gcc.22680 PMID: 30144193
- Magnusson S, Borg Å, Kristoffersson U, Nilbert M, Wiebe T, Olsson H. Higher occurrence of childhood cancer in families with germline mutations in BRCA2, MMR and CDKN2A genes. Fam Cancer. 2008; 7:331–337. https://doi.org/10.1007/s10689-008-9195-7 PMID: 18481196
- Ferla R, Calò V, Cascio S, Rinaldi G, Badalamenti G, Carreca I, et al. Founder mutations in BRCA1 and BRCA2 genes. Annals of Oncology. 2007. p. vi93–8. https://doi.org/10.1093/annonc/mdm234 PMID: 17591843
- 42. Terkelsen T, Christensen LL, Fenton DC, Jensen UB, Sunde L, Thomassen M, et al. Population frequencies of pathogenic alleles of BRCA1 and BRCA2: analysis of 173 Danish breast cancer pedigrees using the BOADICEA model. Fam Cancer. 2019; 18:381–388. https://doi.org/10.1007/s10689-019-00141-9 PMID: 31435815
- Soenderstrup IMH, Laenkholm A V, Jensen MB, Eriksen JO, Gerdes AM, Hansen TVO, et al. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG. Acta Oncol (Madr). 2018; 57:95–101. https://doi.org/10.1080/0284186X.2017.1398415 PMID: 29164974
- Rogers KJ, Fu W, Akey JM, Monnat RJ. Global and disease-associated genetic variation in the human Fanconi anemia gene family. Hum Mol Genet. 2014; 23:6815–6825. <u>https://doi.org/10.1093/hmg/ ddu400 PMID: 25104853</u>
- Seal S, Thompson D, Renwick A, Elliott A, Kelly P, Barfoot R, et al. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet. 2006; 38:1239–1241. https://doi.org/10.1038/ng1902 PMID: 17033622
- Berwick M, Satagopan JM, Ben-Porat L, Carlson A, Mah K, Henry R, et al. Genetic heterogeneity among fanconi anemia heterozygotes and risk of cancer. Cancer Res. 2007; 67:9591–9596. <u>https://doi.org/10.1158/0008-5472.CAN-07-1501 PMID: 17909071</u>
- Rahman N, Seal S, Thompson D, Kelly P, Renwick A, Elliott A, et al. PALB2, which encodes a BRCA2interacting protein, is a breast cancer susceptibility gene. Nat Genet. 2007; 39:165–167. https://doi.org/ 10.1038/ng1959 PMID: 17200668
- Hyde SM, Rich TA, Waguespack SG, Perrier ND, Hu MI. CDC73-Related Disorders. GeneReviews®. 1993. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20301744. PMID: 20301744
- Saha N, Ropa J, Chen L, Hu H, Mysliwski M, Friedman A, et al. The PAF1c Subunit CDC73 Is Required for Mouse Hematopoietic Stem Cell Maintenance but Displays Leukemia-Specific Gene Regulation. Stem Cell Reports. 2019; 12:1069–1083. https://doi.org/10.1016/j.stemcr.2019.03.010 PMID: 31031188
- Ciuffi S, Cianferotti L, Nesi G, Luzi E, Marini F, Giusti F, et al. Characterization of a novel CDC73 gene mutation in a hyperparathyrodism-jaw tumor patient affected by parathyroid carcinoma in the absence of somatic loss of heterozygosity. Endocr J. 2019; 66:319–327. https://doi.org/10.1507/endocrj.EJ18-0387 PMID: 30799315
- Bluteau O, Sebert M, Leblanc T, Peffault de Latour R, Quentin S, Lainey E, et al. A landscape of germ line mutations in a cohort of inherited bone marrow failure patients. Blood. 2018; 131:717–732. https:// doi.org/10.1182/blood-2017-09-806489 PMID: 29146883
- 52. Diets IJ, Waanders E, Ligtenberg MJ, van Bladel DAG, Kamping EJ, Hoogerbrugge PM, et al. High yield of pathogenic germline mutations causative or likely causative of the cancer phenotype in selected children with cancer. Clin Cancer Res. 2018; 24:1594–1603. <u>https://doi.org/10.1158/1078-0432.CCR-17-1725 PMID: 29351919</u>
- Whitworth J, Smith PS, Martin JE, West H, Luchetti A, Rodger F, et al. Comprehensive Cancer-Predisposition Gene Testing in an Adult Multiple Primary Tumor Series Shows a Broad Range of Deleterious

Variants and Atypical Tumor Phenotypes. Am J Hum Genet. 2018; 103:3–18. https://doi.org/10.1016/j. ajhg.2018.04.013 PMID: 29909963

- Morak M, Massdorf T, Sykora H, Kerscher M, Holinski-Feder E. First evidence for digenic inheritance in hereditary colorectal cancer by mutations in the base excision repair genes. Eur J Cancer. 2011; 47:1046–1055. https://doi.org/10.1016/j.ejca.2010.11.016 PMID: 21195604
- 55. Kuhlen M, Borkhardt A. Trio sequencing in pediatric cancer and clinical implications. EMBO Mol Med. 2018; 10. https://doi.org/10.15252/emmm.201708641 PMID: 29507082
- Chang VY, Wang JJ. Pharmacogenetics of Chemotherapy-Induced Cardiotoxicity. Current Oncology Reports. Current Medicine Group LLC 1; 2018. https://doi.org/10.1007/s11912-018-0696-8 PMID: 29713898
- Cubeddu L. Drug-induced Inhibition and Trafficking Disruption of ion Channels: Pathogenesis of QT Abnormalities and Drug-induced Fatal Arrhythmias. Curr Cardiol Rev. 2016; 12:141–154. https://doi. org/10.2174/1573403x12666160301120217 PMID: 26926294
- Chompret A. The Li-Fraumeni syndrome. Biochimie. 2002; 84:75–82. https://doi.org/10.1016/s0300-9084(01)01361-x PMID: 11900879
- Hisada M, Garber JE, Fung CY, Fraumeni JF, Li FP. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst. 1998; 90:606–611. <u>https://doi.org/10.1093/jnci/90.8.606</u> PMID: 9554443
- Villani A, Shore A, Wasserman JD, Stephens D, Kim RH, Druker H, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. Lancet Oncol. 2016; 17:1295–305. <u>https://doi.org/10.1016/S1470-2045</u> (16)30249-2 PMID: 27501770
- Walsh MF, Kennedy J, Harlan M, Kentsis A, Shukla N, Musinsky J, et al. Germline BRCA2 mutations detected in pediatric sequencing studies impact parents' evaluation and care. Cold Spring Harb Mol case Stud. 2017; 3. https://doi.org/10.1101/mcs.a001925 PMID: 28655807